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Abstract 
Shiga toxin-producing E. coli (STEC) are a major cause of food-borne illness in the 
United States and worldwide.  Most STEC cases resolve without complication, however 
approximately 10% progress to severe disease including hemolytic uremic syndrome (HUS).  
Shiga toxin (Stx), the main virulence factor of STEC, is an AB5 toxin.  The enzymatic A-subunit 
cleaves the 28S rRNA, inhibiting protein synthesis, while the homopentameric B-subunit binds 
Stx to the cellular receptor, globotriaosylceramide.  Stx has two major antigenic forms, Stx1 and 
Stx2, and minor subtypes Stx1c and d and Stx2a-h.  Epidemiologic studies have found that Stx2 
subtype a (Stx2a) is associated with more severe disease than Stx1, and other Stx2 subtypes, 
although closely related to Stx2a, exhibit discrepancies in disease severity.  Despite the fact that 
infection with Stx2a producing STEC are correlated with more severe disease, there is currently 
no predictive indicator of which cases will progress to HUS.  Endothelial cells are suggested to 
play a role in HUS; therefore, we investigated whether there is a difference in susceptibility of 
endothelial cells from different vascular beds to Stx1 and Stx2 subtypes that affects progression 
to severe disease.  Human umbilical vein endothelial cells (HUVECs), glomerular microvascular 
endothelial cells (GMECs) and cerebral cortex microvascular endothelial cells (BMECs) were 
fairly insensitive (ED50 > 0.2 µg/ml) to metabolic inhibition by Stx1, Stx2a, Stx2b, Stx2c and 
Stx2d.  Human dermal microvascular endothelial cells (dHMECs) were quite sensitive (ED50 ≤ 
1.9 x 10
-1
 µg/ml) to all toxins except Stx2b.  Susceptibility to Stx correlated with the ability of 
the toxins to bind each cell type which was influenced by expression level of the receptor.  In 
addition to affecting the kidney, 20-30% of HUS cases involve central nervous system 
dysfunction.  The role of Stx in leading to neurological complications is not well understood.  
Stx must either damage brain endothelial cells or pass through the blood brain barrier (BBB) to 
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access susceptible cells.  To determine if Stx accesses susceptible cells in the brain by damaging 
endothelial cells of the BBB, we utilized primary and immortalized cell lines.  Neither 
immortalized microvascular endothelial cells from the cerebral cortex of mice (bEnd.3) nor 
primary human BMECs were susceptible to Stx2a, suggesting that direct toxicity to endothelial 
cells is not how Stx weakens the BBB.  It is instead likely that inflammation plays a significant 
role in loss of BBB integrity. 
In order for Stx to exert toxicity on cells it must bind, undergo endocytosis and retrograde 
transport to the endoplasmic reticulum and then reach the cytosol.  While multiple studies on Stx 
transport have been reported, most utilize cell lines without direct involvement in human disease.  
Little is known about trafficking in primary cells pertinent to disease and if it differs from that in 
cell lines.  We used a genome wide siRNA screen to investigate the trafficking pathway of Stx2a 
in primary renal proximal tubule epithelial cells (RPTECs).  The screen both confirmed 
previously reported cellular components involved in Stx trafficking and identified novel factors.  
Since there is currently no treatment for HUS, these results provide possible targets for future 
therapeutics. 
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I.  Shiga toxin-producing Escherichia coli and Shiga toxin background 
 
Shiga toxin-producing E. coli and O157:H7 
Shiga toxin-producing Escherichia coli (STEC) are part of the enterohemorrhagic family 
of E. coli (EHEC).  As of 2011, each year in the United States alone, STEC is estimated to cause 
approximately 265,000 illnesses with 3,600 requiring hospitalization and 30 deaths (1).  The 
most prevalent disease causing form in the United States is O157:H7 (1).  O157:H7 had not been 
seen in human disease prior to its isolation in 1982 as the culprit in two outbreaks with 
symptoms progressing to hemorrhagic colitis (2).  Following the identification of E. coli 
O157:H7 as an emerging food-borne pathogen, it has become a major public health concern.   
 
Transmission of O157:H7 and progression of Shiga toxin disease 
Warm-blooded mammals are known to be the main reservoirs of O157:H7 in the 
environment.  Cattle have been the best documented source of O157:H7 as they are 
asymptomatic carriers of the bacteria (3); however sheep, goats and pigs are among other 
animals shown to shed O157:H7 (4,5).  Originally linked to transmission by contaminated beef 
products (2), multiple other food sources have been found to be contaminated with bacteria and 
linked to outbreaks.  Additional sources of contamination now include dairy products, fruits, 
vegetables, water supplies and unpasteurized juices (6–10).  Furthermore, it has been shown that 
O157:H7 can be spread via person-to-person transmission (11).       
Shiga toxin disease follows a well-established progression.  Three to four days after 
ingestion of as few as less than 100 colony forming units (CFU) of O157:H7 (12), individuals 
begin to experience watery diarrhea that can progress to include severe abdominal cramping, 
bloody diarrhea, and hemorrhagic colitis (HC).  Seven to ten days after ingestion of infected 
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material, approximately 90% of cases resolve with no further complications.  The additional 10% 
of cases progress further to the life threatening condition, hemolytic uremic syndrome (HUS), 
defined by a triad of symptoms including hemolytic anemia, thrombocytopenia and renal failure.  
HUS is fatal in 2-5% of cases and disproportionally affects children, the elderly and the 
immunocompromised (13,14).  Additionally, approximately 20-30% of cases are associated with 
neurological complications ranging from cognitive impairment, aphasia, seizures, altered 
consciousness, lethargy, cortical blindness to coma (15–18).  
 
Shiga toxin  
Shiga toxin (Stx) is one of the main virulence factors of STEC, including E. coli 
O157:H7.  Stx is an AB5 toxin comprised of a single A-subunit and a homopentameric B-subunit 
(Figure 1.1) (19). The enzymatically active A-subunit cleaves the N-glycosidic bond at adenine 
4324 in 28S ribosomal RNA, inactivating the ribosome and inhibiting protein synthesis (20,21).  
Inhibition of active ribosomes initiates the ribotoxic stress response (RSR) which triggers 
activation of stress-activated protein kinases (SAPKs) and subsequent downstream signaling 
events (22,23).  The B-subunit of the toxin creates the binding portion, which binds the 
glycolipid cellular receptor globotriaosylceramide (Gb3) (24–26).   
STEC are capable of producing two antigenic forms of Stx, Stx1 and Stx2, which share 
approximately 57% amino acid identity (Figure 1.2) (27,28).  While the two toxins share 
significant structural homology and the same mechanism of action, there is a significant 
difference in the potency of the toxins.  Stx1 is reported to be 10 times more cytotoxic to 
cultured cells in vitro, while Stx2a is 100 times more lethal in an animal model (29,30).  
Epidemiologic studies also show that individuals infected with strains producing either Stx2 
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alone or Stx1 and Stx2 have more severe disease and are more likely to progress to HUS than 
those not expressing Stx2 (14,31,32).   
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Figure 1.1.  Stx1 and Stx2a holotoxin crystal structures. Stx holotoxins consist of a single A-
subunit (green) and a homopentameric B-subunit (each monomer represented by a different 
color).  Images created using PyMOL from PDB structures 1DM0 (Stx1) (33) and 4M1U (Stx2a) 
(34). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stx2a Stx1 
A 
B5 
6 
 
                       
 
B. Stx1 and Stx2a Subunit Sequence Alignments 
A-subunit 
               10        20        30        40        50        60 
Stx1   KEFTLDFSTAKTYVDSLNVIRSAIGTPLQTISSGGTSLLMIDSGTGDNLFAVDVRGIDPE 
Stx2a  R...I....QQS..S...S..TE.S...EH..Q.T..VSV.NHTPPGSY....I..L.VY 
 
               70        80        90       100       110       120 
Stx1   EGRFNNLRLIVERNNLYVTGFVNRTNNVFYRFADFSHVTFPGTTAVTLSGDSSYTTLQRV   
Stx2a  QA..DH....I.Q.....A....TAT.T....S..T.ISV..V.T.SMTT..........   
 
              130       140       150       160       170       180 
Stx1   AGISRTGMQINRHSLTTSYLDLMSHSGTSLTQSVARAMLRFVTVTAEALRFRQIQRGFRT   
Stx2a  .ALE.S....S....VS...A..EF..NTM.RDAS..V..................E..Q   
 
              190       200       210       220       230       240 
Stx1   TLDDLSGRSYVMTAEDVDLTLNWGRLSSVLPDYHGQDSVRVGRISFGSINAILGSVALIL   
Stx2a  A.SE-TAPV.T..PG..........I.N...E.R.E.G........NN.S....T..V..   
 
              250       260       270       280            290        
Stx1   NCHHHASRVARMASDEFPSMCPADGRVRGITHNKILWDSSTLGAILMRR-----TISS   
Stx2a  ....QGA.SV.AVNE.SQPE.QIT.DRPV.KI.NT..E.N.AA.F.N.KSQFLY.TGK     
 
B-subunit 
               10        20        30        40        50        60        
Stx1   TPDCVTGKVEYTKYNDDDTFTVKVGDKELFTNRWNLQSLLLSAQITGMTVTIKTNACHNG 
Stx2a  A-..AK..I.FS...E........DG..YW.S.....P..Q...L........SST.ES.  
 
 
Stx1   GGFSEVIFR-- 
Stx2a  S..A..Q.NND   
 
 
Figure 1.2. Surface representation (A) and sequence alignment for Stx1 and Stx2a (B).  (A) 
Crystal structures highlight the location of conserved amino acids (light grey in A-subunit and 
dark grey in B-subunit) and varying amino acids (green in A-subunit and cyan in B-subunit).  
Images created using PyMOL. (B) Full alignment of A- and B-subunits shown with conserved 
amino acids represented with dots and missing with dashes.  Alignments created using BLASTP 
(NCBI/BLAST).     
A. 
Stx1 Stx2a 
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Genetics and regulation of Stx 
The genes for Stx, StxA and StxB  (35), are encoded by lamboid phage.  The phage are 
capable of lysogenizing susceptible E. coli and integrating in to the DNA.  StxA and StxB are 
encoded in the late gene region of the phage, under the control of the late gene promoter (36–38).  
H-19B and 933W are two well characterized phage that carry the genes for Stx1 and Stx2a 
respectively (27,28,36,37).  Susceptible E. coli are not limited to lysogeny by only Stx1 or Stx2a, 
but can be found to harbor one or multiple phage.  
Following exposure of the bacteria to DNA damage, such as treatment with DNA 
synthesis targeting antibiotics (39) or exposure to host-cell produced H2O2 (40), the bacterial 
stress response or ‘SOS response’ becomes activated, sending the phage in to the lytic cycle.  
During the lytic cycle both phage and toxin are produced.  Unlike other AB5 toxin-producing 
bacteria such as Vibrio cholerae (41,42) and Bordetella pertussis (43),  which have dedicated 
toxin secretion systems, STEC have no coordinated mechanism for release of the toxin from the 
periplasm.  Therefore, the lytic cycle also activates production of phage lysis genes and bacterial 
cell lysis is necessary for release of Stx.  Previous research has shown that susceptible, 
nonpathogenic commensal E. coli in the intestine can be infected by phage encoding Stx released 
during lysis (44,45).   
 
 
Stx receptor and membrane aspects 
 
Stx1 and Stx2a share approximately 62% amino acid identity in the B-subunit and the 
glycolipid globotriaosylceramide (Gb3) has been characterized as the receptor for both toxins 
(46–48,26).  Gb3, also known as the P
k
 blood group antigen, consists of the carbohydrate moiety 
Galα1-4Galβ1-4Glc (known as Pk trisaccharide or CD77) and a ceramide tail.  Gb3 is found in 
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lipid rafts (detergent-resistant membranes) within the cell membrane.  In addition to Gb3, lipid 
rafts are enriched in cholesterol, sphingolipids and phospholipids (49,50).   
The modification of functional groups on the sugars present in the P
k
 trisaccharide has 
been shown to alter binding specificity of the toxins.  It was observed that specific O-
polysaccharides of certain lipopolysaccharides (LPS) from E. coli, including O107/O117, were 
capable of specifically inhibiting Stx2, but not Stx1 toxicity to Vero cells (51).  Structural 
examination of O117 found that it shared a similar terminal disaccharide as Gb3 with the 
exception of the hydroxyl group at C 2 being replaced with a N-acetyl group.  Further 
examination has gone on to show that in solid phase binding assessments, Stx1 preferentially 
binds Gb3 whereas Stx2 prefers a N-acetylated analogue of Gb3 (52,53).    
The ceramide portion of the Gb3 receptor contains a variable length fatty acid chain.  
Extraction of Gb3 from human renal tissue revealed fatty acid chains ranging from 14 to 24 
carbons.  Binding analysis of Stx1 to semisynthetic fatty acid chains corresponding to the 
varying lengths of renal Gb3 species revealed that heterogeneous mixtures resulted in the highest 
binding affinity (54).  Variability in the lipid portion of Gb3 isolated from various tissues may 
affect the presentation, or distribution, of the carbohydrate moiety at the cell membrane and thus 
may affect toxin binding.  Distributions which allow for engagement of the most receptor 
binding sites on the toxin will promote the strongest interactions.   Injection of mice with 
125
I-
labeled Stx has shown that Stx1 and Stx2a preferentially deposit at different sites within the body 
(55,56).  After 1h, Stx1 is enriched in the lungs, while Stx2 is found in the kidneys (55).  Binding 
locations for each toxin may be influenced by the composition of Gb3 species within the 
particular tissue.   
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Additional insight in to receptor interaction and binding for Stx has come from crystal 
and nuclear magnetic resonance (NMR) structures of the toxins bound to receptor analogues.  
Ling et al. reported the first structure of the Stx1 B-subunit bound to an analogue of Gb3 referred 
to as P
k
-MCO (8-(methoxycarbonyl)-octyl trisacharide) (57).  P
k
-MCO contains the P
k
 
trisaccharide of Gb3 with a modified ceramide portion.  Prior to solving the structure of the B-
subunit, it was hypothesized by modeling and comparison to similar proteins that Stx would 
contain one to two binding sites per monomer (58–60).  The crystal structure however showed 
P
k
-MCO could bind at three different sites per monomer, for a theoretical total of 15 binding 
sites in the pentameric B-subunit.  Analysis of individual binding sites identified site 2 as having 
the strongest density and highest occupancy compared to site 1 and site 3.  Additionally, all three 
sugars of P
k
-MCO were found to engage residues of the B-subunit in site 2 (57). Taken together 
it suggested that site 2 was the high affinity receptor site for each monomer.  The importance of 
site 2 was confirmed by a NMR solution structure of Stx1B bound to a Gb3 analogue (61). 
Until recently, the field has been at a disadvantage as no structure of the more clinically 
relevant Stx2a bound to Gb3 or a Gb3 analogue was available.  In 2014, Jacobson et al. reported 
the first structure of Stx2a bound to a disaccharide analogue of Gb3 (34).  Interestingly, as was 
seen in solid phase binding assays, the structure was finally obtained by crystallizing Stx2a with 
a Gb3 analogue termed P
kNAc which contained a terminal αGal-NAc as opposed to the αGal 
found in Gb3.  Unlike the Stx1 structure, occupancy of only two receptor binding sites was 
observed per monomer, totaling 10 receptor binding sites on the pentamer compared to 15 for 
Stx1 (34).  As was predicted by Fraser and colleagues in 2004 after solving the structure of the 
Stx2a holotoxin, receptor site 3 was found to be unoccupied on all five monomers due mostly to 
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steric hindrance caused by the A-subunit protruding through the pore of the B-subunit (62).  For 
two monomers, steric hindrance was specifically attributed to residue Trp33 (34).      
 
Endocytosis and retrograde transport of Stx 
 In order for Stx to reach the cytosol of susceptible cells and inhibit protein synthesis it 
must enter and traffic through the cell (Figure 1.3).  The endocytosis of Stx predominantly 
occurs from lipid raft regions of the membrane where Gb3 has been found to concentrate (63,64). 
Stx enters cells in three main ways: (1) clathrin mediated endocytosis (65,66), (2) caveolae 
dependent endocytosis (67), and (3) inducing membrane invaginations (68).  Inhibiting a single 
form of endocytosis has shown that Stx can still be taken in to the cell (69); therefore, one or all 
pathways may be working at the same time in cells.  In most instances for endocytosis to occur, 
signaling events must take place at the membrane.  Tyrosine kinase activity has been reported to 
be associated with Shiga toxin uptake in multiple cell types including the kinases Syk in HeLa 
cells (70), Yes in the human renal adenocarcinoma cell line ACHN (64), and Syk and Lyn in 
Burkitt’s lymphoma Ramos cells (71,72).  
Once inside the cell Stx undergoes retrograde transport to the early endosome.  Clathrin 
and retromer have been found to be important for this step.  Stx can pass from the early 
endosome to recycling endosomes.  Stx travels from early and recycling endosomes to the trans-
Golgi network (TGN), bypassing late endosomes and the late endocytic pathway (73).  At a step 
either in the endosome or TGN, prior to reaching the endoplasmic reticulum (ER), the A-subunit 
is cleaved in to two fragments, A1 and A2.  The Stx A-subunit harbors the consensus sequence, 
Arg-X-X-Arg, for cleavage by the endoprotease furin (74) which locates to the the TGN and to a 
lesser extent the cell surface and endosomes.  Garred et al. showed that furin cleaves the A-
subunit following Arg251, giving rise to the catalytic A1 fragment consisting of residues 1-251 
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(approximately 27.5 kDa) and the B-subunit associated A2 fragment consisting of residues 252-
293 (approximately 4.5 kDa) (75).  Following cleavage by furin, the A1 and A2 fragments 
remain attached through a disulfide bond between Cys242 and Cys261 in the respective 
fragments (35,76).  
From the TGN, Stx travels through the Golgi apparatus to reach the ER.  Inside the ER 
the disulfide bond between the A1 and A2 fragments is reduced.  Reduction of the disulfide bond 
is not a highly efficient process and a large portion of disulfides are not reduced (77).  Only the 
A1 fragment translocates to the cytosol, therefore if reduction of the disulfide bond does not 
occur, A1 remains attached to the rest of the protein and is unable to reach the ribosomes in the 
cytosol and exert toxicity.  A1 fragments that are liberated are suggested to use the misfolded 
protein ER-associated degradation (ERAD) pathway to translocate from the ER to the cytosol.  
The Stx A-subunit has been shown to complex with the chaperone HEDJ/Erdj3 and associate 
with the Sec61 translocon (78).  In order to exert its N-glycosidase activity on ribosomes, the A1 
fragment must avoid degradation by the proteosome in the cytosol.  Interestingly, it has been 
proposed that Stx and other AB toxins do so in part by having few to no lysine residues in the 
translocated A-subunit fragment (79).  In order for ubiquitin to mark a protein for degradation by 
the proteosome it must be attach to lysine residues (80). Therefore, if the protein lacks lysine 
residues, it can bypass the ubiquitin-conjugating enzymes and escape detection. 
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Figure 1.3.  Intracellular trafficking of Stx.  After binding receptor (red rectangle) at the 
plasma membrane, Stx is endocytosed to the endosome.  From the endosome, Stx undergoes 
retrograde transport to the trans-Golgi network, then thru the Golgi apparatus to the endoplasmic 
reticulum (ER).  From the ER, the Stx A-subunit (green oval) translocates to the cytosol. 
 
 
 
 
 
II.  Subtypes of Shiga toxin 
 
Stx subtypes 
  
In addition to the two antigenic forms of Stx, Stx1 and Stx2, each toxin has been 
characterized to have multiple subtypes and variants.  There has been a significant amount of 
confusion in the literature in reference to the classification of these subtypes and variants as they 
have been identified.  In this dissertation, we will use the nomenclature put forward in 2009 by 
Flemming Scheutz et al. (81).  In the proposal it was suggested that toxins should be classified 
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first on type (Stx1 or Stx2), then on subtype.  Subtypes in the proposal are based on nucleotide 
and amino acid sequence similarity to the types.  A variant is then designated as a sequence with 
amino acid differences within a given subtype (81).  Within the types, Stx1 has subtypes a, c and 
d (82,83) and Stx2 has subtypes a-h (84–90).   
 Stx subtypes are clinically relevant to human disease since Stx2 subtypes are associated 
with differences in disease progression and severity.  The highly related Stx2a, Stx2c and Stx2d 
are more commonly associated with severe disease including HC and HUS (91–94) than the 
more distantly related subtypes Stx2b, Stx2e, Stx2f and Stx2g.  Stx2e is generally associated 
with causing edema disease in swine (87,88,95) and has rarely been documented to cause 
diarrhea or more severe disease in humans (96–98).  The lack of potency of Stx2e in humans has 
been attributed to receptor preference.  While Stx1 and most Stx2 subtypes bind the identified 
receptor Gb3, Stx2e preferentially binds the receptor globotetraosylceramide (Gb4) (99). Further 
discussion of subtypes will focus on Stx1a (referred to as Stx1) and Stx2a-d, which are the most 
pertinent to human disease and the primary focus of studies presented in this dissertation.        
 
 
 
Interaction of subtypes with receptor  
 
Receptor binding preferences of Stx1 and Stx2a have been the subject of multiple studies 
(25,52,53,100); however, the receptor(s) for Stx2b, c and d are not well established.  The 
subtypes 2a, 2c and 2d vary by a few amino acids, with some mapping to regions important for 
binding.  The structure of Stx2a bound to a disaccharide analog of Gb3 was solved by Jacobson 
et al. (34) (Figure 2.1). When the amino acid differences in the Stx2c B-subunit are modeled on 
the Stx2a structure, polymorphism D16N maps to binding site 1, while D24A is not located 
within a binding site.  The affect these polymorphisms exert on binding to Gb3 are not well 
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characterized.  In subtype Stx2d the type strain carries the same B-subunit polymorphisms as 
Stx2c; however, the B-subunit of a variant strain is identical to that of Stx2a.  Additionally, 
strains of Stx2d in which the terminal two amino acids, G296 and E297, are cleaved by elastase, 
terming it activatable have been identified (101).  Activation by elastase increases the potency of 
the toxin on Vero cells, in mouse infection models, and has been seen in cases of human disease 
(101,102).  It is speculated that elastase found in the human intestine is capable of activating the 
toxin during the disease process (102).  Subtype Stx2b is significantly less potent than a, c, or d 
and shares the least amount of amino acid identity with Stx2a.  In addition to D16N in site 1, 
Stx2b contains polymorphisms S31N and S54N in site 2 and lacks the terminal two amino acids 
N69 and D70.   
 
III.  Role for Shiga toxin in disease 
 
Stx and HUS 
 
The term hemolytic uremic syndrome (HUS) was first used to 1955 by von Gasser and 
colleagues to describe children experiencing thrombocytopenia, thrombi within the renal 
microvasculature, and hemolytic anemia that was not related to an immune system cause (103).  
Thirty years later, Karmali and colleagues finally proved the link between STEC and HUS 
(104,105).  Since that point, E. coli O157:H7 has been recognized as the predominant serotype of 
STEC associated with HUS in the United States, however other serotypes are more prevalent in 
other parts of the world (9,106,107).  Stx alone has been shown to be sufficient to cause HUS 
since the administration of purified toxin to animals recapitulates many of the symptoms seen 
during human disease (108,109).   Stx has also been found in the kidney of patients who 
succumb to disease, indicating it is capable of leaving the intestine and entering the circulation 
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(110).  Additionally, in 2011 one of the worst outbreaks of STEC occurred in Germany with 
close to 4,000 reported cases.  Interestingly, the outbreak was not caused by an O157 strain, but 
instead was attributed to an enteroaggregative E. coli (EAEC) O104:H4 which had acquired the 
ability to produce Stx2 (111,112).  In addition to the large number of cases in this outbreak, there 
was an unusually high rate of HUS with 22% of patients progressing to severe disease (9,113).  
Prior to this outbreak O104:H4 had rarely been associated with HUS; however, in previous 
instances the bacteria had also acquired the phage encoding the stx genes (112).  The acquisition 
of Stx by O104:H4 and its ability to result in a high rate of HUS further confirmed the 
importance of Stx (9,113).  The major pathology of Stx associated HUS in humans is observed in 
the kidney and can include glomerular endothelial cell swelling, detachment of endothelial cells 
from basement membrane and fibrin enriched thrombi predominantly in the microvasculature of 
the glomeruli (103).   
 While the principle site of damage during Stx-associated HUS is the kidney, other organs 
can also be involved (114).  The highest proportion of involvement outside of the kidney is 
observed in the central nervous system (CNS) with 20-30% of cases involving neurological 
complications.  The prognosis worsens in cases of HUS that include CNS dysfunction (15,17).  
Challenge of mice with purified Stx2a leads to neurological symptoms similar to those seen in 
human disease including lethargy, paralysis and seizures (115,116), though the exact role of Stx 
in CNS dysfunction has yet to be elucidated.   
 
 
 
Stx subtypes and progression to severe disease 
 
  The progression of STEC infections to severe disease likely involves both host and 
microbial factors making predicting those cases that will progress to HUS more complicated.  
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The potency of Stxs determined in vitro does not always correlate well in vivo since Stx1 is more 
potent to cells in culture yet Stx2a is significantly more potent to animals and humans.  To try 
and gain a better understanding of the potency and potential of Stxs to lead to severe disease, 
multiple groups have undertaken typing studies to match Stx types and subtypes with clinical 
outcome in STEC sample cohorts.  While the results of these studies are influenced by the strains 
circulating in the area of the study and it is difficult to factor in effects of the E. coli host, some 
observations have still be made providing insight in to potency of various Stxs.  Friedrich et al. 
investigated 5487 stool samples submitted to the Institute for Hygiene and Microbiology 
(Warzburg, Germany) for routine diagnosis that were obtained from cases of HUS, bloody 
diarrhea and watery diarrhea (92).  STEC was isolated from 626 samples and stx2a was the 
predominant type in samples from cases of HUS, followed by strains carrying both stx2a and 
stx2c together.  Similarly, in 173 samples of STEC in Finland analyzed by Eklund et al., 42% (72 
strains) carried stx2a and stx2c together (91).  In addition to Stx2a, Stx2c was the only other 
subtype associated with cases of HUS.  Strains that carried stx1 did not lead to any cases of HUS.  
This was a finding echoed in a study by Persson et al. with a Danish STEC cohort where strains 
isolated from 20 patients who progressed to HUS were found to carry subtype Stx2a (11/20), 
Stx2c (1/20) or Stx2a and 2c together (8/20) while none harbored Stx1 (93).  Of the 241 total 
cases in this study with a documented clinical outcome 40% were children under 7 years of age.  
Strikingly however, 18 of the 20 cases of HUS were in children under 7 making age strongly 
associated with the progression to HUS (93).  While each of these studies may be biased to the 
location in which they were conducted, the overall results suggest an increased association of 
Stx2, especially subtypes a and c, with HUS as compared to Stx1. 
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 The correlation of Stx2 subtypes with more severe disease and the development of HUS 
has also been seen in retrospective studies of cohorts within the United States.  Jelacic et al. 
analyzed all stool samples submitted to microbiology labs in Montana between May 1998 and 
June 2000 (~6300 samples total) for the presence of STEC and found 85 that were positive 
(117).  This group analyzed results focusing on E. coli serotype and found that all O157:H7 
isolates harbored stx2 subtype genes and 81% of these patients experienced bloody diarrhea.  
Only 46% of non-O157:H7 STEC were positive for stx2 subtype genes and 58% of these patients 
reported bloody diarrhea suggesting an increased pathogenic potential for Stx2 producing 
O157:H7 strains.   
Donohue-Rolfe et al. used a neurological complications/lesions gnotobiotic piglet model 
to investigate the contribution of Stx1 and Stx2 to disease severity (118).  Variants of strains 
EDL933 (capable of producing Stx1 and Stx2a) deficient in stx1 or stx2a and a stx2a deleted 
strain of 86-24 (capable of producing Stx2a only) were created and used to infect piglets.  
Similar to what is seen in human disease, 90% of 86-24 and 85% of 933stx1
-
 infected piglets 
were affected while 16% of those infected with 933stx2
-
developed lesions.  Fewer cases of 
disease were observed using EDL933 than with the EDL933stx1
-
strain suggesting that strains 
containing only stx2 genes may be capable of causing more severe disease than those with both 
genes.  Interestingly, Muniesa et al. found that toxin production could vary within a single 
outbreak (119).  When inducing outbreak isolates it was observed that some produced low levels 
of phage and some produced high levels.  Further investigation determined that the low toxin 
producing isolates contained two phage encoding Stx2, whereas the high toxin producers only 
had one.  The presence of a second Stx2 encoding phage was capable of repressing toxin 
expression.  When correlated with disease, higher levels of phage release and toxin lead to more 
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severe symptoms, whereas all asymptomatic individuals were infected with a low-phage 
producing isolate.  Low-phage producing isolates were also associated with some symptomatic 
individuals.  
 
Stx toxicity to endothelial cells and a role for inflammation 
Pathology results show damage to the vasculature and endothelial cells during HUS.  
Stx1 was first reported to be directly cytotoxic to endothelial cells using human umbilical vein 
endothelial cells (HUVECs) (120).  Obrig et al. also showed in this initial study that 
subconfluent or actively dividing HUVECs were more susceptible to actions of Stx than those in 
a confluent state (120).  Cytotoxic effects on HUVECs were confirmed to be a direct result of the 
toxin and not LPS, with no toxicity observed at levels up to 10 µg/ml LPS (121).  HUVECs 
though are significantly less sensitive to Stx than epithelial kidney cells from green monkeys 
(Vero cells). One theory for the reduced sensitivity of large vein endothelial cells for Stx is 
reduced expression of the Gb3 receptor on the surface of cells.  Resting HUVECs contain as little 
as 0.06 nM Gb3/mg of cells as compared to 80 nM Gb3/mg of cells for Vero cells (121).  The 
cytotoxicity of Stx to HUVECs was found to be increased following the stimulation of cells with 
pro-inflammatory mediators including TNF-α, IL-1β, and bacterial lipopolysaccharide (LPS)  
(122–124).    
Stx associated HUS however affects the microvasculature (103,125).  Human dermal 
microvascular endothelial cells (dHMECs) are highly susceptible to the cytotoxic effects of both 
Stx1 and Stx2a and express surface Gb3 (126).  A role for these cells in HUS has yet to be 
established, though thrombi and petechial purpura in the skin have each been noted in HUS 
patients at autopsy (125,127).   
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Based on the clinical manifestations of HUS, the interaction of Stx with microvascular 
endothelial cells of the glomeruli and brain are of increased interest.  Initial studies by Obrig and 
colleagues reported renal microvascular endothelial cells to be approximately a 1000-times more 
sensitive to Stx1 than HUVECs and 1000-times more sensitive to Stx2a than Stx1 (128).  The 
increased toxicity observed for renal microvascular endothelial cells was attributed to levels of 
Gb3 expression.  Obrig et al. found renal microvascular endothelial cells to contain 50 times 
more Gb3 than could be extracted from HUVECs (128).  Later studies however failed to 
recapitulate the results seen by Obrig and colleagues.  Using a more stringent isolation technique 
for microvascular cells from the glomerulus, van Setten et al. found the sensitivity of glomerular 
microvascular endothelial cells (GMVECs) to be inversely related to confluency of the cells, 
though the overall sensitivity was similar to HUVECs (129). Additionally, others have reported 
GMVECs to be resistant to Stx and express little Gb3 (130).  A role for pro-inflammatory 
mediators in increasing the susceptibility of GMVECs to Stx has been reported.  van Setten et al. 
increased the cytotoxicity of Stx1 on GMVECs by stimulation with TNF-α (129).    
Similar to GMECs, the sensitivity of microvascular endothelial cells isolated from the 
cerebral cortex of the brain (BMECs) have been reported to vary significantly between research 
groups.  Initially BMECs were found not to be susceptible to Stx up to reports as high as >10 
µg/ml and contain little Gb3 (130–132).  Stimulation of BMECs with TNF-α or IL-1β was 
reported to increase sensitivity to Stx mediated toxicity by up to 10
3
 (131,132).  Bauwens et al. 
however recently reported BMECs to be sensitive to Stx with an ED50 of less than 10 ng/ml for 
both Stx1 and Stx2a without the presence of inflammatory mediators (133).  While sensitivity of 
cells to Stx is thought to be associated with levels of Gb3 expression, Storck et al. showed that 
this did not hold true in human pancreatic ductal adenocarcinoma cells.  The susceptibility of 
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different cell lines tested did not correlate with Gb3 levels, therefore, there may be other 
components affecting toxicity (134).    
 
Effect of Stx on gene expression 
 As opposed to causing direct damage, Stx at concentrations that cause minimal inhibition 
of protein synthesis can induce changes in gene expression of endothelial cells.  An initial 
microarray analysis of the gene expression pattern of HUVECs following stimulation with a dose 
1/10
th
 the LD50 of Stx1 or Stx2a revealed that both toxins only alter regulation of approximately 
20 genes in the cells after 24 h (135).  Of the genes regulated by toxin, most were predominantly 
cytokines, chemokines, cell adhesion molecules and immune response or apoptotic associated 
transcription factors.  Stx1 and Stx2a were observed to regulate both similar and unique genes.  
A similar study was conducted with Stx2a using microvascular endothelial cells (136).  
Microarray analysis of the gene expression pattern of dHMECs stimulated with a concentration 
of Stx2a resulting in only a 10% inhibition in protein synthesis showed that Stx2a altered only 
2.5% of the genes tested.  Similar to HUVECs, Stx2a regulated chemokines and cytokines in 
dHMECs.  Interestingly, two of the most highly induced genes were the chemokine receptors, 
CXCR4 and CXCR7 and an increase was also noted in their common ligand, stromal cell-derived 
factor-1 (SDF-1) (136).  The importance of the CXCR4/SDF-1 signaling pathway in the 
vasculature has been established (137–140) and an overactive pathway can lead to kidney 
pathology (137,139).  In vivo Stx challenge increased expression of CXCR4 and SDF-1.  
Impairment of the CXCR4/SDF-1 pathway in both in vitro and in vivo studies resulted in 
improvement during Stx2a challenge suggesting that a balance in the signaling pathway is 
necessary to maintain homeostasis.  Additionally, SDF-1 levels have been found to be higher in 
patients with E. coli O157:H7 who progress to HUS than those who resolve the infection without 
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complication (136).  The increase in SDF-1 in patients may tip the pathway in the wrong 
direction and lead to kidney pathology. 
Subinhibitory concentrations, which are more likely to be similar to concentrations cells 
are exposed to during STEC infection, appear to be important in promoting inflammatory 
responses from endothelial cells.  Additional cell types have also been found to upregulate 
expression of and/or release pro-inflammatory cytokines, chemokines and cell adhesion 
molecules in response to Stx, contributing to an increased inflammatory and pro-thrombogenic 
environment (141–143).    
 
Contributions of B-subunit signaling on vascular response in HUS 
 While some responses to toxin, including the inhibition of protein synthesis (20,144) and 
regulation of gene transcription (136), require the holotoxin, the B-subunit alone elicits responses 
which increase the pro-thrombotic nature of vascular cells.  Treatment of endothelial cells with 
Stx holotoxin caused the release of unusually large von Willebrand factor (ULVWF) (145), 
however similar release can be stimulated by Stx1B or Stx2B alone (146,147).  VWF is a large 
plasma glycoprotein which plays an important role in forming clots to repair the endothelium 
following injury (148).  VWF secreted due to injury or stimulus is generally of the unusually 
large form (ULVWF) which is highly active.  ULVWF binds to platelets through activated 
glycoprotein Ib-IX-V platelet receptor and can form thrombi (149).  To prevent aberrant thrombi 
formation, ULVWF is cleaved by the enzyme ADAMTS13 to smaller, less reactive fragments, 
though the activity of ADAMTS13 is delayed in the presence of Stx (145).  The release of vWF 
induced by Stx1B or Stx2B reached a maximum within 5 minutes under flow conditions, 
suggesting the release is in response to a signaling event (146).  In addition, induced release of 
ULVWF by the B-subunits required the engagement and clustering of Gb3 in lipid rafts 
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containing cholesterol and caveolin-1 (146).  Challenge of ADAMTS13
-/-
 mice with Stx2B 
resulted in animals developing anemia and thrombocytopenia, supporting the pathologic 
potential of the Stx B-subunit alone.  Recent findings also suggest that Stx1B and 2B induce the 
secretion of ULVWF by separate pathways (147) which could potentially play a role in the 
increased likelihood of Stx2 infections progressing to HUS.   
 
Animal models  
 Different animal models have been utilized in an attempt to recapitulate all aspects of 
human disease, though no single model has been able to yet.  The mouse model is one of the 
most widely used for Stx challenge (150).  Unfortunately, Gb3 expression differs in the mouse 
from that in the human which likely affects the presentation of pathology (151).  However, 
following Stx challenge, mice have been found to exhibit similar neurological symptoms to those 
seen in humans and may provide a useful model for studying Stx associated CNS dysfunction 
(115,116).  
With the lack of success in fully recapitulating disease in other models, a nonhuman 
primate model was established.  Taylor et al. established the first primate model for Stx using 
baboons which has been used by them and other groups in additional studies (152). The main 
caveat of this model has been that the pathological outcome of treatment with Stx depends on 
how the toxin is administered, i.e. one bolus or multiple smaller doses over an extended period of 
time.  Initially, Stx1 was administered to animals as a single bolus of either a high dose (2 µg/kg) 
or a low dose (0.2 to 0.05 µg/kg).  The outcome in both groups was renal shutdown and death of 
the animals.  Pathological findings in the high dose animal group included hemorrhage, 
thrombosis and necrosis in the GI tract and little visible change in the kidneys.  However, low 
dose animals exhibited less severe hemorrhaging in the GI tract, but more prominent thrombosis 
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and necrosis in the kidneys.  The renal glomeruli and proximal tubules showed the most damage.  
In addition to pathological changes, there were increases in the cytokines TNF and IL-6 in the 
urine, but only a minimal increase in IL-6 in the blood, suggestive of a limited systemic 
inflammatory response (152).  A direct comparison of a single dose of Stx1 or Stx2a showed a 
dose dependent response with 100 ng/kg of Stx1 and 50 ng/kg of Stx2a causing complete 
lethality (153).  Average time to death was shorter in animals treated with a lethal dose of Stx1 
than Stx2a (57.5 h verses 121.3 h), however pathology and inflammatory markers differed at the 
time of death.  Challenge with both toxins resulted in renal damage with decreased urine output, 
proteinuria and thrombocytopenia.  A comprehensive examination of inflammatory markers 
revealed different patterns for each toxin (153). 
Interestingly, Stx1 delivered as a single, rapid injection of 100 ng/kg caused HUS in the 
baboon, however splitting the dose over the course of four 25 ng/kg injections administered 12 
hours apart did not recapitulate HUS (154).  The addition of LPS to the divided doses of Stx1 
resulted in HUS in the animals.  Pathology following co-administration of Stx1 and LPS 
included thrombotic microangiopathy, fibrin and detached glomerular endothelial cells.   
 Similar to what is seen in human disease, an equivalent dose (by weight) of the more 
potent Stx2a administered over the course of four injections resulted in illness and death (109).  
Stx2a induced clinical changes including increased urinary IL-6, decreased platelets and 
glomerular TMA including endothelial cell damage.   
The baboon model can be manipulated to recapitulate much of the pathology seen in the 
human GI tract and kidneys during disease.  However, with the exception of a few animals, 
baboons do not show signs of the neurological complications that can accompany up to 30% of 
HUS cases in humans.   
24 
 
 
IV.  Scope of this dissertation 
Many questions still remain as to how STEC cause uncomplicated disease in certain 
individuals, yet lead to severe disease in others.  Additionally, the difference in potency of Stx1, 
Stx2a and toxin subtypes is still not fully understood.   In the studies in this dissertation we aim 
to better understand the potency differences of Stx1 and Stx2 subtypes.  In chapter II the potency 
of Stx1 and Stx2 subtypes a-d will be analyzed on endothelial cells from different vascular beds 
to determine if susceptibility of endothelial cells to different toxins has an effect on progression 
to severe disease.  More recently, the importance of dysfunction of organs other than the kidney 
during HUS is being appreciated for its role in disease outcome.  Chapter III will look 
specifically at endothelial cells of the blood brain barrier (BBB) to understand how their 
susceptibility to Stx may play a role in CNS dysfunction associated with HUS.  In order to better 
understand the mechanism of Stx in vivo, it is important to understand how Stx interacts with 
cells that are involved in disease.  Many studies have been completed in cell types not relevant to 
disease and therefore the results may not be applicable in vivo.  In chapter IV, the intracellular 
trafficking of Stx2a will be analyzed in primary renal proximal tubule epithelial cells.  Finally, 
chapter V will discuss future research directions that result from these studies. 
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Chapter II 
Potency of Stx Variants on Endothelial Cells of Different Origins 
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Abstract 
The main virulence factor of Shiga toxin-producing Escherichia coli (STEC) is Shiga toxin 
(Stx). Stx inactivates ribosomes by irreversibly removing an adenine from the 28S rRNA, 
leading to inhibition of protein synthesis.  In its most severe form, Stx causes dysfunction of the 
endothelium and culminates in sequela due to hemolytic uremic syndrome (HUS).  There are two 
major antigenic forms of Stx, Stx1 and Stx2, with additional subtypes of Stx2 (Stx2a to –h).  
Isolates from cases of disease have been found to harbor a single toxin or multiple subtypes.  
Toxin subtypes have been found to display varying levels of toxicity both in vitro and in vivo 
and epidemiologically.  While the interaction of Stx1 and Stx2a with primary endothelial cells 
has been characterized, it is also important to understand the interactions of the toxin subtypes 
with these cells.  In this study we investigated the relative potencies of Stx1 and the Stx2 
subtypes Stx2a, Stx2b, Stx2c and Stx2d on endothelial cells from various vascular beds.  
Endothelial cells from different origins varied in their susceptibility to Stx.  Dermal 
microvascular cells were the most sensitive to all Stxs and exhibited the highest levels of Gb3 
expression and binding by toxin.   
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Introduction 
Shiga toxin producing E. coli (STEC) are responsible for a significant number of cases of 
food-borne illness both within the United States and worldwide each year (1).  STEC infections 
cause a range of symptoms from diarrhea to hemorrhagic colitis.  Approximately 10% of those 
infected with STEC progress to severe disease including hemolytic uremic syndrome (HUS) 
(155).  HUS is characterized by the triad of symptoms hemolytic anemia, thrombocytopenia and 
uremia.  Additionally, a subset of individuals infected with STEC display neurological 
complications ranging from disorientation to seizures and coma (15,16,18).   
Shiga toxin (Stx) is the main virulence factor of STEC and has been implicated as an 
important component of disease (155).  Stx is an AB5 toxin, composed of the catalytic A-subunit 
and five identical monomers that form the B-subunit or binding portion of the toxin.  The B-
subunit of Stx binds to cells which express the glycolipid receptor globotriaosylceramide (Gb3).  
Binding of the B-subunit to receptor expressing cells allows for the toxin to undergo endocytosis 
and retrograde transport to the endoplasmic reticulum (ER) (73).  Following transport to the ER, 
the A-subunit translocates to the cytosol.  Within the cytosol, the A-subunit inactivates 
ribosomes by irreversibly removing adenine 4324 from the 28S rRNA, leading to inhibition of 
protein synthesis (20).   
Two major antigenic forms of Stx exist, Stx1 and Stx2 (28), which share approximately 
60% amino acid identity.  In addition to Stx1 and Stx2, both forms have subtypes with which 
they share significant amino acid identity.  Currently, Stx2 has eight different identified subtypes 
a-h (84–90).  The nomenclature for Stx subtypes has varied since their first identification and for 
the purposes of this study we will follow classifications and nomenclature put forward in 2009 
(81).  The Stx2 from strain EDL933 is designated as Stx2a and according to this classification 
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Stx2a, Stx2c and Stx2d share a high degree of homology whereas Stx2b, Stx2e and Stx2g are 
more distantly related.  Stx1 and Stx2 differ at multiple amino acids in the B-subunit, however 
the Stx2 subtypes Stx2a, Stx2c and Stx2d vary by only a few amino acid substitutions (Figure 
2.1).    Infection with STEC expressing Stx2 is more often associated with severe disease than 
Stx1 (14,31,32,156).  The classification for Stx2 subtypes is reflected in disease epidemiology as 
Stx2a, Stx2c and Stx2d are more frequently associated with severe disease including 
hemorrhagic colitis and HUS than Stx2b or Stx2e (91–94).  Slight differences have been 
observed in the receptor binding preferences of Stx2a, Stx2c and Stx2d (157–159).  However, 
Stx2e which is associated with an edema disease in neonatal piglets (88) has been shown to 
prefer the receptor globotertraosylceramide (Gb4) (160).  Strains of STEC may carry one or more 
types of Stx at a time.   
Endothelial cells are suggested to play a role in severe complications of STEC infection 
including hemorrhagic colitis and HUS (103).  Significant heterogeneity is observed in 
endothelial cells, both between those of the large vessels and the microvasculature and between 
endothelial cells from different vascular beds (161).  Large vessel endothelial cells, human 
umbilical vein endothelial cells (HUVECs), were reported to be susceptible to the action of Stx, 
though high concentrations of toxin were necessary (120).  During severe disease, histological 
findings in the kidney show involvement of the microvasculature in thrombotic microangiopathy 
(TMA) (125).  In this study, the potency and binding of Stx1 and Stx2 subtypes a-d on 
endothelial cells derived from various vascular beds was investigated to determine if the 
susceptibility of endothelial cells to different toxins has an effect on progression to severe 
disease.  
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Figure 2.1.  Sequence alignments and structural comparison of Stx1 and Stx2 subtypes.  (A) 
Sequence alignment comparison of the B-subunit of Stx2a to Stx2b, Stx2c, Stx2d and Stx1.  Dots 
depict identical amino acids and dashes depict missing amino acids.  Alignment was made using 
BLASTP (NCBI/BLAST).  (B)  Structural comparison of the top view and binding face of the B-
subunit.  Individual subunits of the Stx2a disaccharide bound B-subunit (PDB: 4M1U) depict 
Stx1 or Stx2 subtypes.  Stx2a is shown in cyan; green, Stx2b; yellow, Stx2c; gray, Stx2d; pink, 
Stx1.  Dark blue indicates amino acid polymorphisms with respect to Stx2a.  Images were made 
using PyMOL. 
 
 
B.  Structural comparison of Stx1 and Stx2 subtypes
 
A.  Sequence alignment comparison of Stx1 and Stx2 subtypes
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Materials and Methods 
 
Toxin purification. Stx was purified from phage-induced cultures as previously described 
(29,159).  Briefly, overnight cultures were grown in cation stabilized Mueller-Hinton broth, 
diluted 1/100 in fresh broth and grown at 37
o
C with shaking for 2 h.  Ciprofloxacin was added at 
20 ng/ml and cultures were grown overnight.  Cultures were centrifuged and filter sterilized.  
Stepwise ammonium sulfate precipitation was applied to the filtrate and toxin was in the 40 to 
80% fraction.  Stx was purified by AffiGel Blue chromatography and size exclusion (Superdex 
75) chromatography.  Stx1, Stx2a and Stx2c were obtained from the Biodefense and Emerging 
Infectious Diseases Research Resources Repository (BEI, Manassas, VA).  Stx supernatant 
preparations were processed as described above and collected after filter sterilization.  
Lipopolysaccharide (LPS) content of purified proteins and supernatants was determined by the 
limulus amoebocyte lysate (LAL) assay (Lonza).   
 
Cell culture.  Human umbilical vein (HUVEC, CC-2519, Lot 0000178776) and neonatal dermal 
microvascular (dHMEC, CC-2516, Lot 0000317328) endothelial cells were obtained from 
Clonetics (Lonza, Walkersville, MD) and propagated in Endothelial Cell Medium without 
phenol red (ScienCell, Carlsbad, CA).  Cells were harvested with TrypKit (Lifeline Cell Technologies, 
Walkersville, MD) according to manufacturer’s protocol.  Human primary kidney glomerular 
(GMEC, ACBRI 128, Lot 128.01.0M.01.0R) and cerebral cortex (BMEC, ACBRI 376, Lot 
376.04.0H.0U.0Y) microvascular endothelial cells were obtained from Cell Systems Corporation 
(Kirkland, WA) and were propagated in Complete Classic Medium with serum, CultureBoost 
and Bac-Off
®
 antibiotic (Cell Systems, Kirkland, WA).  Cells were harvested with the Passage 
Reagent System (Cell System) according to manufacturer’s protocol.  The CDC.HMEC-1 line 
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was maintained in MCDB 151 medium supplemented with 10 mM L-glutamine, 10 ng/ml 
epidermal growth factor, 1 µg/ml hydrocortisone, 10% fetal bovine serum (FBS), 50 µg/ml 
gentamycin sulfate and 100 µg/ml kanamycin sulfate. 
 
Toxicity assay.  Stx was serially diluted in 20 µl of medium in sterile, black, clear, flat-bottom 
96-well plates (Corning, Tewksbury, MA).  Cells were plated (in 60 µl of medium) at 
subconfluent or confluent numbers, as indicated in cells per well for each cell type: 
                           
                          TABLE 2.1.  Plating densities for endothelial cells. 
Cells Type Subconfluent (cells/well) Confluent (cells/well) 
HUVEC 1 x 10
3 
6 x 10
3 
dHMEC 6 x 10
3 
1.2 x 10
4 
GMEC 3 x 10
3 
8 x 10
3 
BMEC 1.5 x 10
3 
8 x 10
3 
 
 
Toxin-treated cells were incubated at 37
o
C in 5% CO2.  After 42 h the medium was removed and 
50 µl of fresh medium containing 10% (vol/vol) alamarBlue (AbD Serotec, Raleigh, NC) was 
added.  Cells were incubated in the presence of alamarBlue for a total of 3 h.  Fluorescence was 
read at 590 nm on a FLX-800 fluorimeter (BioTek, Winooski, VT) every 30 min and values 
within the linear range, before depletion of substrate, have been reported.  In assays using TNF-
α, cells were plated at either subconfluent or confluent densities in 60 µl of medium and 
incubated overnight.  TNF-α (10 ng/ml) was added the next day and 24 h later toxin was added.  
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Cells were incubated for an additional 42 h and analyzed as described above.  Dose-response 
curves were plotted as the percentage of untreated cells verses toxin concentration.   
 
Protein synthesis inhibition.  Inhibition of protein synthesis by Stx was assessed using cells 
transduced with luc2P to express a destabilized form of luciferase used previously with Vero 
cells (162).  Briefly, the luc2P gene from the pGL4.11[luc2P] vector (Promega) was cloned in to 
the MigR1 retroviral vector.  HEK GP2-293 cells were used to package the luc2P-MigR1 DNA 
with VSV-g envelope.  Medium containing virus was collected and used for transductions.  HEK 
GP2-293 cells and VSV-g were a gift from Dr. William Miller.  HUVECs were transduced in 12-
well plates for 48 h.  Following transduction luc2P HUVECs were maintained in T75 cm
2
 flasks.  
Serial dilutions of Stx were added to white, tissue culture-treated, 96-well microtiter plates 
(Becton Dickinson, Franklin Lakes, NJ).  Luc2p HUVECs were added (approximately 10
4
 
cells/well) and the plate was incubated 37
o
C in 5% CO2.  After 4 h, cells were washed three 
times with PBS and 25 µl of Superlite luciferase substrate (Bioassay Systems, Hayward, CA) 
was added.  Light produced was measured with a Luminoskan Ascent (Thermo Labsystems, 
Helsinki, Finland).  Due to limited proliferation dHMECs and GMECs were transduced and 
assayed as follows. Cells were plated in the 96-well microtiter assay plates at 2 x 10
3
 cells/well 
and incubated overnight at 37
o
C in 5% CO2.  Luc2P virus was diluted in the appropriate 
endothelial cell medium for each cell type and added to wells at 30% (vol/vol) final well volume.  
After two days, serial dilutions of Stx were added to the cells and the plates were assayed as 
described above.  For assays involving TNF-α, the cytokine (10 ng/ml) was added following the 
two day incubation with virus and cells were incubated for an additional 24 h before being 
analyzed. 
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Flow cytometry to detect toxin binding and Gb3.  For each treatment 5 x 10
4
 cells were used.  
Cells were cooled on ice for 30 min and all subsequent incubations were carried out on ice.  
Cells were incubated for 1 h with 300 ng toxin supernatants or PBS for controls.  Cells were 
washed with cold PBS and incubated with primary antibody for 1 h.  Stx2 subtypes were 
detected using the A-subunit mouse monoclonal antibody 11E10 (BEI, Manassas, VA) diluted 
1:300.  Stx1 was detected using a rabbit polyclonal antibody diluted 1:1000 (163).  Cells were 
washed, stained with Alexa Fluor 488 labeled mouse (product # A11001) or rabbit (product # 
A11008) secondary antibody diluted 1:1000 (Life Technologies) for 1 h, and analyzed by flow 
cytometry (BD FACSCalibur; Becton Dickinson, Franklin Lakes, NJ).  Due to the limited 
number of cells, analysis was performed by collecting 1 x 10
4
 events or all events collected for 5 
min.  Unstained cells, cells incubated only with secondary antibody and cells incubated with 
primary and secondary antibody (no toxin) were used as negative controls.  Gb3 expression on 
cells was analyzed by a 1 h incubation with antibody to Gb3 (clone 38-13, Accurate Chemical & 
Scientific Corporation, Westbury, NY) or PBS for controls.  Cells were washed, incubated for 1 
h with fluorescein isothiocyanate (FITC) conjugated α-rat IgM secondary antibody diluted 1:500 
(AbD Serotec, Bio-Rad, Raleigh, NC) and analyzed by flow cytometry.  Cells were gated for the 
live cell population based on the forward and side scatter.   
 
Pretreatment with TNF-α.  To assess the role of TNF-α, cells were plated in 12-well plates and 
allowed to adhere overnight.  TNF-α (10 ng/ml) was added and 24 h later cells were harvested 
and treated as described above.  As a positive control for TNF-α activity, stimulated HUVECs 
were stained for induction of intercellular adhesion molecule 1 (ICAM-1) expression and 
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analyzed by flow cytometry.  Allophycocyanin (APC) labeled ICAM-1 (CD54) antibody was 
diluted 1:200 (clone HA58, product number 353111, BioLegend, San Diego, CA).  
 
Statistical analysis.  Statistical analyses were performed by One-way t-test, One-way ANOVA 
or unpaired Student’s t-test using Prism5 (GraphPad Software, La Jolla, CA). 
 
 
Results 
 
Toxicity of Stx subtypes to primary endothelial cells.   
To determine the susceptibility of endothelial cells to Stx1 and Stx2 subtypes a-d, we 
measured metabolic activity following a 42 h incubation with toxin.  In initial studies, the dermal 
microvascular cell line CDC.HMEC-1 showed a dose-dependent reduction in metabolic activity 
following treatment with Stx1 or Stx2a, Stx2c and Stx2d (Figure 2.2), but was fairly resistant to 
Stx2b.  A statistically significant reduction in metabolic activity was observed at all 
concentrations for Stx1, Stx2c and Stx2d and for all but the lowest two concentrations tested for 
Stx2a.   The ED50 value for each toxin was calculated and is shown in Table 2.2.  Stx2d (ED50 < 
5 x 10
-7
 µg/ml) was the most potent form of Stx on the CDC.HMEC-1 line.  Stx2c (ED50 8.1 x 
10
-7
 µg/ml) had a similar potency to Stx2d while Stx1 (ED50 3.4 x 10
-6
 µg/ml) and Stx2a (ED50 
1.7 x 10
-4
 µg/ml) were less potent to the cells.  CDC.HMEC-1 were least susceptible to Stx2b 
(ED50 > 0.2 µg/ml), with a statistically significant reduction in metabolic activity observed only 
at 0.2 µg/ml.   
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Figure 2.2.  Potency of Stx to immortalized CDC.HMEC-1 dermal microvascular 
endothelial cells.  Subconfluent cells were exposed to serial dilutions of Stx1 or Stx2 subtypes a-
d.  Following a 42 h incubation with toxin, media was replaced with fresh media containing 
alamarBlue (10% vol/vol).  The reduction of alamarBlue from resazurin to fluorescent resorufin 
by mitochondrial activity was read at 30 min intervals for 3 h.  The 1 h time point is shown.  
Toxin-treated cells are shown as a percent of control cells not receiving toxin.  Dose response 
curves are an average of three experiments with error bars representing the standard deviation of 
the mean. 
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Since immortalization can affect the properties of a cell, we decided to test primary 
human endothelial cells from various anatomical locations, including those assessed for Stx1 or 
Stx2a in previous studies (120,126,128,129,131).  It has previously been shown that actively 
dividing cells are more susceptible to toxin than those in a confluent state (120); therefore we 
examined susceptibility of primary cells under both subconfluent and confluent conditions.  As 
has been seen previously, large vessel umbilical vein endothelial cells (HUVECs) showed little 
sensitivity to Stx1 or Stx2a at either a subconfluent or confluent density (126), and our studies 
demonstrated that HUVECs are similarly resistant to Stx2b, Stx2c and Stx2d (Figure 2.3A and 
2.3B).   
During the course of disease the microvasculature appears to be the primary location 
affected by Stx, therefore, we tested microvascular endothelial cells from different sites.  As seen 
with the dermal endothelial cell line, primary neonatal dermal microvascular cells (dHMEC) 
were susceptible to Stx1, Stx2a, Stx2c and Stx2d at both subconfluent and confluent densities 
(Figure 2.3C and 2.3D).  Subconfluent dHMECs displayed a similar susceptibility to Stx2a, 
Stx2c and Stx2d (ED50 values of 3.2 x 10
-4
, 6.1 x 10
-4
 and 1.6 x 10
-4
 µg/ml respectively).  
dHMECs were less susceptible to Stx1 (ED50 3.7 x 10
-3
 µg/ml) (Table 2.2).  dHMECs were 
resistant to Stx2b in both subconfluent and confluent conditions, with no significant decrease in 
metabolic activity even at the highest concentration.  Subconfluent dHMECs (Figure 2.3C) were 
approximately 100-fold more susceptible to Stx1, Stx2a and Stx2c than confluent dHMECs and 
approximately 10-fold more susceptible to Stx2d (Figure 2.3D and Table 2.2).    
The susceptibility of primary glomerular microvascular cells (GMECs) to Stx has been a 
point of disagreement in the literature.  Obrig et al. reported that renal microvascular endothelial 
cells were extremely sensitive to Stx (128), while others have found that the cytokines TNF-α or 
37 
 
IL-1β are required to sensitize cells (129).  Additionally, others have reported a complete lack of 
susceptibility of GMECs to Stx (130).  In this study, GMECs were insensitive to all toxins tested 
regardless of confluency (Figure 2.3E and 2.3F).  Pre-treatment with TNF-α (10 ng/ml) for 24 h 
did not affect susceptibility of either subconfluent or confluent GMECs to any of the toxins 
(Figure 2.3G and 2.3H).  These results were in agreement with Hughes et al. who were also 
unable to detect any sensitivity to Stx for glomerular endothelial cells obtained from Cell 
Systems (130). 
The sensitivity to Stx of microvascular endothelial cells from the brain (BMECs) also 
varies in published literature.  Published studies have suggested that these cells are either 
susceptible to toxin alone (133,164) or that unstimulated cells are resistant and can be made 
susceptible by stimulation with TNF-α or IL-1β (131,132,165).  We found unstimulated BMECs 
were resistant to all toxins tested (data not shown) and a 24 h incubation with TNF-α (10 ng/ml) 
had no effect on sensitivity of subconfluent or confluent cells (Figure 2.3I and 2.3J).  The TNF-
α used in these studies was verified to be active as a 24 h incubation with BMECs (results shown 
in Chapter III) or HUVECs at 10 ng/ml resulted in upregulation of ICAM-1 expression on cells 
(Figure 2.4). 
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Figure 2.3.  Inhibition of metabolic activity by Stx in primary endothelial cells.  Endothelial 
cells (A) subconfluent HUVEC, (B) confluent HUVEC, (C) subconfluent dHMEC, (D) confluent 
dHMEC, (E) subconfluent GMEC, (F) confluent GMEC, (G) subconfluent GMEC pre-incubated 
with TNF-α, (H) confluent GMEC pre-incubated with TNF-α, (I) subconfluent BMEC pre-
incubated with TNF-α or (J) confluent BMEC pre-incubated with TNF-α were incubated with 
Stx as indicated for 42 h.  The toxin containing media was removed and fresh media containing 
10% alamarBlue was added and incubated for an additional 3 h.  The fluorescent reduction of 
alamarBlue was measured every 30 min.  The 1 h time point is shown for all cell types except 
subconfluent HUVECs which depicts the 3 h time point.  Graphs show toxin-treated cells as a 
percent of the metabolic activity of untreated control cells.  Results are the average of three 
individual experiments run on cells from a single cryoamp and error bars correspond to standard 
deviation of the mean. 
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TABLE 2.2.  ED50 values (µg/ml) of Stx1 and Stx2 subtypes for endothelial cells. 
Cell Type Assay Stx1 Stx2a Stx2b Stx2c Stx2d 
CDC-HMEC.1 
subconfluent 
 
MI 3.4 x 10
-6
 1.7 x 10
-4
 > 0.2 8.1 x 10
-7 
< 5 x 10
-7 
HUVEC 
subconfluent 
 
MI > 1 > 1 > 0.5 > 1 > 1 
HUVEC 
confluent 
 
MI > 1 > 1 > 0.5 > 1 > 1 
HUVEC 
PSI > 0.5 > 0.5 > 0.2 > 0.5 > 0.5 
dHMEC 
subconfluent 
 
MI 3.7 x 10
-3 
3.2 x 10
-4 
> 0.5 6.1 x 10
-4 
1.6 x 10
-4 
dHMEC 
confluent 
 
MI 1.9 x 10
-1 
6 x 10
-2 
> 0.5 4.9 x 10
-2 
4.2 x 10
-3 
dHMEC 
PSI 3.1 x 10
-3 
2.1 x 10
-3
 > 0.2 2.3 x 10
-3
 5 x 10
-4 
GMEC 
subconfluent 
 
MI > 0.5 > 0.5 > 0.2 > 0.5 > 0.5 
GMEC 
confluent 
 
MI > 0.5 > 0.5 > 0.2 > 0.5 > 0.5 
GMEC 
PSI > 0.5 > 0.5 > 0.1 > 0.5 > 0.5 
GMEC treated 
with TNF-α 
subconfluent 
 
MI > 0.5 > 0.5 > 0.2 > 0.5 > 0.5 
GMEC treated 
with TNF-α 
confluent 
 
MI > 0.5 > 0.5 > 0.2 > 0.5 > 0.5 
GMEC treated 
with TNF-α 
 
PSI > 0.5 > 0.5 > 0.1 > 0.5 > 0.5 
BMEC treated 
with TNF-α 
subconfluent 
 
MI > 0.5 > 0.5 > 0.2 > 0.5 > 0.5 
BMEC treated 
with TNF-α 
confluent 
MI > 0.5 > 0.5 > 0.2 > 0.5 > 0.5 
MI= metabolic inhibition assay   PSI= protein synthesis inhibition assay 
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Figure 2.4.  Upregulation of surface ICAM-1 on HUVECs following stimulation with TNF-
α.  HUVECs were incubated with 10 ng/ml TNF-α for 24 h and stained for surface expression of 
ICAM-1 (CD54).  ICAM-1 staining was analyzed by FACS.  Results depict a single trial. 
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Inhibition of protein synthesis by Stx subtypes.   
The N-glycosidase activity of Stx allows the protein to cleave an adenine from the 
ribosomal RNA and inhibit protein synthesis (20).  In cell types including Vero cells, the 
inhibition of protein synthesis by Stx correlates with loss of metabolic activity and loss of cell 
viability (76).  However, in other cell types, including mesangial cells, significant inhibition of 
protein synthesis is observed in the absence of the loss of cell viability (166).  While a loss in 
metabolic activity was not observed at a longer time point, it does not indicate that protein 
synthesis is not inhibited at earlier points following toxin exposure.  To assess the ability of Stx1, 
Stx2a, Stx2b, Stx2c and Stx2d to inhibit protein synthesis we transduced primary endothelial 
cells to express a destabilized form of luciferase, where protein synthesis is proportional to 
luciferase production.  A small, but statistically significant decrease in protein synthesis was 
observed in HUVECs with all toxins tested at high concentrations (Figure 2.5A).  The ability to 
inhibit protein synthesis was similar for Stx1 (ED50 3.1 x 10
-3
 µg/ml), Stx2a (ED50 2.1 x 10
-3
 
µg/ml) and Stx2c (ED50 2.3 x 10
-3
 µg/ml) in dHMECs.  Stx2d (ED50 5 x 10
-4
 µg/ml) was 
approximately 10-fold more potent than Stx1, Stx2a and Stx2c, while Stx2b (ED50 > 0.2 µg/ml) 
was not significantly potent at any concentration (Figure 2.5B and Table 2.2).  Untreated 
GMECs and GMECs pre-incubated with TNF-α were resistant to protein synthesis inhibition by 
Stx1 and all Stx2 subtypes (Figure 2.5C and 2.5D).    
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Figure 2.5.  Inhibition of protein synthesis by Stx in primary endothelial cells.  Endothelial 
cells, (A) HUVEC, (B) dHMEC, (C) GMEC or (D) GMEC pre-incubated with TNF-α were 
transduced to express the luc2P gene.  Following a 4 h treatment with Stx as indicated, luciferase 
substrate was added and relative light units were measured.  The relative light units of control 
cells not receiving toxin were used as 100% protein synthesis.  Cells treated with toxin are 
shown as a percent of control cells.  Results are the average of three individual experiments run 
on cells from a single cryoampule and error bars correspond to standard deviation of the mean. 
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Toxin binding to primary endothelial cells. 
 In order to exert its effects Stx must bind to the cell and be endocytosed.  Resistance to 
toxin can occur either because the toxin does not bind to the cell or it binds, but following 
endocytosis it does not undergo retrograde transport and is instead shunted to the lysosomal 
pathway (167).  To determine if the toxins were capable of binding the different endothelial cells 
we used flow cytometry.  Binding of Stx1, but no binding of the Stx2 subtypes was detected on 
HUVECs (Table 2.3 and Table 2.4 respectively).  Stx1, Stx2a, Stx2c and Stx2d bound well to 
dHMECs, consistent with the previously observed ability of the toxins to inhibit metabolic 
activity and protein synthesis in these cells.  Stx2b, which did not inhibit metabolic activity or 
protein synthesis, was not capable of binding dHMECs (Table 2.3 and 2.4).  Stx2 subtypes were 
unable to bind to either untreated GMECs or BMECs both untreated and those pre-incubated 
with TNF-α (Table 2.4).  Minimal, but statistically significant, binding of Stx1 to TNF-α 
stimulated GMECs was observed (Table 2.3).   
 
Gb3 content of endothelial cells. 
 To determine if the lack of binding of Stx to cells was due to receptor expression we 
analyzed cells for the toxin receptor Gb3.  HUVECs and GMECs lacked detectable expression of 
Gb3 and stimulation of GMECs with TNF-α did not cause an increase in Gb3 expression on cells 
(Table 2.5).  Due to limited proliferation we were not able to test the Gb3 expression of primary 
dHMECs.   However, since the CDC.HMEC-1 line showed similar sensitivities to the panel of 
toxins, we determined the Gb3 expression of these cells.  CDC.HMEC-1 cells expressed Gb3 in 
agreement with the susceptibility of these cells to toxin (Table 2.5).  
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TABLE 2.3.  Stx1 binding to primary endothelial cells. 
 
Cell Type                                               Geometric Mean of the Fluorescent Intensity 
                                                  2
o
 ab Alone                    No toxin                                 Stx1______ 
 
HUVEC
***
                                  17.9 ± 1.6                          ND                                  68 ± 14.9 
 
dHMEC
****
                                 10.2 ± 1.1                          ND                                1646 ± 492 
 
GMEC                                        13.9 ± 0.2                     37.2 ± 5.3                            46.7 ± 8.4 
 
GMEC treated with TNF-α*        23.7± 1.8                        48 ±1.9                              66.7 ± 7.8 
 
BMEC                                         13 ± 1.1                        30.6 ± 6.5                            35.3 ± 8.5 
 
BMEC treated with TNF-α         14.8 ± 2.2                       78 ± 6.5                              88.3 ±10.7 
 
Results are reported as average and standard deviation for three experiments, except BMEC 
treated with TNF-α (n=2).  Results have been gated for live cells.  ND- not determined.  
Significant difference was determined by comparing Stx1 values with those of the no toxin 
control, with the exception of HUVEC and dHMEC which were compared to 2
o
 ab.  Significance 
value for GMEC treated with TNF-α determined by unpaired Student’s t-test, *p=0.0161.  
Significance values for HUVEC and dHMEC determined using log10 transformed values, 
***p=0.0008 and ****p<0.0001 by unpaired Student’s t-test. 
 
 
TABLE 2.4.  Stx2 subtype binding to primary endothelial cells. 
 
Cell Type                                                                               Geometric Mean of the Fluorescent Intensity 
                              2
o
 ab Alone           No toxin                 Stx2a                  Stx2b                  Stx2c                Stx2d 
 
HUVEC                 21.3 ± 2.3                 ND                   23.7 ± 1.6           21.8 ± 1.6          23.9 ± 3.7           21.7 ± 2.4 
 
dHMEC                 10.2 ± 0.4                 ND                   306 ± 132
***
       10.5 ± 0.7         484 ± 208
***
      264 ± 123
***
 
 
GMEC                   13.97 ± 0.5          15.4 ± 1.4              16.7 ± 0.1           16.3 ± 1.2          16 ± 1.1              15.9 ± 0.9 
 
GMEC treated       23.6 ± 1.8             23 ± 1.8                28.9 ± 2.9            26 ± 1.8            26.6 ± 2.6           24.6 ± 2.7 
with TNF-α 
 
BMEC                   13.9 ± 0.7            14.8 ± 1.3              14.7 ± 1.3            15 ± 0.7             15.2 ± 1.5          14.4 ± 0.7 
 
BMEC treated       19.4 ± 1.8             21 ± 0.7                21.5 ± 1.7            20.1 ± 2             21.6 ± 0.1          19.7 ± 0.3 
with TNF-α 
 
Results are reported as average and standard deviation for three experiments, except BMEC treated with TNF-α 
(n=2).  Results have been gated for live cells. ND- not determined.  Significance values for dHMEC determined 
using log10 transformed values, ***p<0.0001 by One-way ANOVA. 
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TABLE 2.5.  Cell surface Gb3 on endothelial cells. 
 
Cell Type                                                   Geometric Mean of the Fluorescent Intensity 
                                                                     2
o
 ab Alone                                      Gb3                                         
 
HUVEC                                                          7.2 ± 2.4                                      8.4 ± 1.3 
 
CDC.HMEC-1
** 
                                             7.1 ± 1.5                                      29.8 ± 1.9
 
 
GMEC                                                             13.9 ± 2                                       13.6 ± 1.6 
 
GMEC treated with TNF-α                             12.5 ± 1.1                                    11.8 ± 0.6 
 
Results are reported as average and standard deviation for three experiments, except 
CDC.HMEC-1 (n=2).  Results have been gated for live cells. **p= 0.0058 (unpaired Students t-
test). 
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Discussion 
 In its worst manifestation infection with STEC can lead to hemolytic uremic syndrome 
(HUS), characterized by hemolytic anemia, thrombocytopenia and acute renal failure.  A role for 
the microvasculature in HUS is suggested and damage is in part mediated by responses to toxin.  
Infections with STEC that produce Stx2a have been associated with a higher risk of progressing 
to severe disease than those that produce Stx1 alone (14,31,32).  Infections with STEC that carry 
the genes for Stx2c and activatable Stx2d have also been isolated from cases of hemorrhagic 
colitis and HUS (93,102).  In this study we determined the potency of Stx1 and Stx2 subtypes a-
d on endothelial cells from various vascular beds, including those from the kidney and brain, 
which are proposed to play key roles in disease.  By comparing Stx subtype differences on 
endothelial cells of various anatomical origins we hoped to gain insight in to variations in disease 
severity and the likelihood of progressing to serve disease.   
 The toxicity of Stx to endothelial cells was first observed in HUVECs, however high 
concentrations of toxin were necessary to cause reductions in cell viability (120).  Several studies 
have established that HUVECs can become sensitized to Stx by upregulation of receptor 
expression using components such as sodium butyrate, TNF-α, lipopolysaccharide (LPS) and IL-
1β (122,123,168).  Correlating with a lack of sensitivity, untreated HUVECs have a low Gb3 
content (126).  In agreement with these results we found that HUVECs were relatively 
insensitive, with a small, but statistically significant reduction in protein synthesis at high 
concentrations for all the toxins tested.  Additionally, Gb3 was not detected on HUVECs, 
although we have shown that other glycolipids can bind Stx (100,159), and perhaps promote 
internalization.  Large vessel endothelial cells however are not proposed to play a significant role 
during infection. 
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Dysfunction in vivo during disease is suggested to be the result of damage to the 
microvasculature.  A predominant feature of HUS is damage to the renal glomeruli, leading to 
thrombotic microangiopathy (TMA).  Damage manifests as glomerular endothelial cell swelling 
and detachment from the basement membrane and the accumulation of thrombi within the 
glomerulus (103,125). Currently, it is unclear whether direct damage to the kidney endothelial 
cells, direct damage to other cells in the kidney, or glomerular accumulation of thrombin 
activated in more distal tissues is responsible for kidney damage in human disease.   
Direct damage to kidney endothelial cells no longer seems to offer a complete 
explanation.  In early studies, Obrig and colleagues reported that unstimulated renal 
microvascular endothelial cells isolated from human kidney contained approximately 50 times 
more Gb3 and were over 1000 times more sensitive to Stx1 than HUVECs (128,169).  However, 
using a more stringent purification protocol for glomerular endothelial cells, van Setten et al. 
showed that GMECs have some susceptibility to Stx1 in a subconfluent state that is reduced 
upon confluency (129).  Studies by other groups, and the studies reported here, have found 
glomerular endothelial cells to be fairly resistant to toxin.  An increase in sensitivity to Stx has 
been observed following pre-incubation with inflammatory mediators (129).  The renal 
endothelial cells isolated by Obrig may have been contaminated with cell types other than 
GMECs, which are sensitive to Stx (29,170).     
In our study, GMECs obtained from Cell Systems (Kirkland, WA) were not sensitive to 
any of the toxins tested in either a subconfluent or confluent state.  Likewise, we were unable to 
increase sensitivity by pre-incubation with TNF-α.  These results, however, are consistent with 
the observation of Hughes et al. who reported little Gb3 and a lack of sensitivity to Stx with 
GMECs from multiple different donors obtained from Cell Systems (130).  Variability in the 
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response to Stx1 has been observed in HUVECs and GMECs isolated from different donors 
(122,124,129).  In isolated HUVEC lines derived from 55 separate individuals, only 7% were 
found to actually be sensitive to Stx (124,171).  Additionally, in an early study Louise and Obrig 
reported unpublished data that if HUVECs were resistant to Stx1 up to a concentration of 10 nM, 
they were unable to observe any synergistic sensitivity with TNF (122).  Our lack of observed 
toxicity to cells correlated with no significant Stx2 binding and no detectable Gb3 in both 
unstimulated and TNF-α stimulated GMECs.  Minor, but significant, Stx1 binding to stimulated 
cells was observed.  Microvascular cells from the cerebral cortex obtained from Cell Systems 
also lacked sensitivity to Stx and will be discussed in further detail in Chapter III of this 
dissertation. 
The extent of direct toxicity of Stx on glomerular microvascular endothelial cells appears 
uncertain; therefore, the role of other cells within the kidney must be considered.  In addition to 
endothelial cells, podocytes and mesangial epithelial cells are found within the glomerulus and 
are important for its structure and function.  Both cell types express Gb3, are affected by Stx in 
vitro and show signs of damage in vivo (151,166).  In vitro, podocytes undergo apoptosis in 
response to activation of signaling pathways by Stx (172,173). In vivo, binding of Stx has been 
observed to both podocytes and mesangial cells in glomeruli of a fatal case of HUS (110,174).  
Markers of podocyte damage have been identified in the urine of HUS patients (175) and 
swollen podocytes have been observed following challenge in the baboon model of disease and 
in some acute cases of HUS in humans (152,176).  While less is known about a role for 
mesangial cells during HUS, podocytes are an integral part of the filtration barrier.  Injury to 
podocytes resulting in proteinuria and loss of these cells could lead to vascular damage that 
would allow Stx to access highly sensitive renal epithelial cells.        
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 Tubule epithelial cells offer another target for toxin in the kidney.  Human renal proximal 
tubule epithelial cells (RPTECs) are highly sensitive to toxin, contain high levels of Gb3, 
(29,170) and stimulation with Stx1 causes RPTECs to release TNF-α and other pro-inflammatory 
cytokines (177).  Damage is observed in HUS patients in the acute phase of disease, with tubule 
cells showing loss of the brush border, cell flattening and vacuolization.  In a mouse model, 
which is not confounded by glomerular TMA due to the lack of Gb3 expression on murine 
GMECs, a renal tubule specific knockout of Gb3 caused complete protection of the renal 
epithelium from Stx2a induced damage (176).    
Mounting evidence suggests that Stx may increase dysfunction by inducing coagulation 
abnormalities in the endothelium and promoting a pro-thrombotic environment.  Elevated levels 
of tissue factor have been found in children with STEC associated HUS (178) and 
thrombomodulin is decreased by incubation with Stx in TNF-α pre-treated GMECs (179).  
Additionally, levels of prothrombin fragment 1 + 2, tissue plasminogen activator (tPA) and D-
dimers are all found to be increased in HUS patients (180–182).  Results also suggest that Stx 
can activate endothelial cells.  Stx, both the holotoxin and B-subunit, induced signaling for the 
release of unusually large vonWillenbrand Factor (vWF) from endothelial cells (145,146).  
Additionally, in vitro, exposure to Stx1 increased platelet adhesion and thrombus formation on 
the CDC.HMEC-1 dermal line under conditions of high sheer stress in a process that also 
involved vWF (183).  In this study we found primary neonatal dHMECs highly susceptible to 
Stx1, Stx2a, Stx2c and Stx2d, but resistant to Stx2b.  dHMECs expressed Gb3 and bound all 
toxins except Stx2b. A role for dermal microvascular cells during STEC infection has yet to be 
identified.  However, taken together these results suggest that dHEMCs are susceptible to Stxs 
and could be activated and/or damaged by toxin during STEC infection.  This could result in an 
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increase in the thrombotic nature of the cells and possible initiation of thrombi formation.  
Thrombi and petechial purpura have each been observed in the skin at autopsy in a HUS patient 
(125,127).  Likewise, in addition to the predominant pathology in the kidney and dysfunction of 
the central nervous system (CNS), multiple other organs are also found to be involved in cases of 
HUS.  TMA lesions and thrombi have been noted in the pancreas, liver, heart, lungs, and spleen 
(114). 
Additionally, HUS is associated with an increase in inflammation, although the role this 
response plays in disease is not yet fully understood.  Monocytes and macrophages have been 
suggested to be a source of pro-inflammatory cytokines.  In vitro studies have shown both cells 
release TNF-α and IL-1β in response to stimulation with Stx (142,143).  TNF-α has been 
reported to upregulate Gb3 on certain human cells, increasing their sensitivity to Stx (122,165) 
and TNF-α and IL-6 have also been reported to be increased in the urine of HUS patients (184).  
However, there are conflicting reports on a role for TNF-α using a mouse model.  Opposing 
reports were published as to the benefit of knocking out TNF-α on animal survival after Stx 
injection (185,186).  These studies varied significantly in the toxin concentrations administered 
and it was shown that improvement in survival of knockout mice was only observed at sub-lethal 
doses.  Interestingly, in human endothelial cells in vitro, Stx at levels that cause little to no 
inhibition of protein synthesis have been found to lead to significant changes in gene expression, 
including upregulation of cytokines, chemokines, and cell adhesion molecules (135,136,187).    
Overall, the epidemiological differences seen during infection with Stx1 or various 
subtypes of Stx2 cannot be explained by the susceptibility of endothelial cells to toxin alone.  It 
is probable that multiple factors including toxicity to other renal cells, distal activation, 
inflammation and factors specific to the infecting bacteria all influence the progression to severe 
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disease.  Unfortunately, the lack of an animal model that recapitulates all of the components of 
HUS makes it difficult for a full understanding of clinical disease.  The identification of an 
appropriate animal model may open the path to answering many of these questions.       
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Chapter III 
 
Susceptibility of Brain Microvascular Endothelial Cells to Stx2a 
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Abstract 
Infection with Shiga toxin (Stx)-producing E. coli (STEC) can lead to severe complications 
including hemolytic uremic syndrome (HUS).  HUS is often associated with complications in 
addition to renal injury, the most common of which is neurological dysfunction.  
Epidemiologically, of the two antigenic forms of Stx, Stx1 and Stx2, Stx2 is more often 
associated with severe disease.  Mice challenged with purified Stx2a exhibit similar neurological 
complications to those observed during the course of human disease.  Stx is suggested to target 
endothelial cells that express the glycolipid receptor, globotriaosylceramide (Gb3).  The Gb3 
expression and susceptibility to Stx2a of microvascular endothelial cells from the mouse (bEnd.3 
cells) and human (BMECs) cerebral cortex were studied.  Both bEnd.3 and BMECs were 
resistant to Stx2a and lacked Gb3 expression. 
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Introduction 
Hemolytic uremic syndrome following diarrheal infection (D+ HUS) is the primary cause 
of acute renal failure in children (103).  Shiga toxin-producing E. coli (STEC) are a major cause 
of enteric infections related to food borne illness (1).  Approximately 10% of STEC infections 
progress to HUS, characterized by thrombocytopenia, hemolytic anemia, and acute renal failure, 
with an approximate 5% mortality rate (155).  While HUS predominantly involves the kidneys, 
disease can be further complicated by additional sequela, the most prominent of which is central 
nervous system (CNS) dysfunction.  HUS with CNS dysfunction occurs in approximately 20-
30% of cases and is correlated with a more severe prognosis (15–17).  Progression to severe 
complications including HUS and CNS dysfunction disproportionately affects children (<5 
years) and the elderly (188).   
Shiga toxin (Stx) is the primary virulence factor of STEC and is implicated in 
involvement in HUS and CNS complications.  The two major antigenic forms of Stx, Stx1 and 
Stx2 (28), share approximately 60% amino acid identity, however Stx2 is more commonly 
associated with progression to severe disease (14,31,32).  Stx is an AB5 toxin consisting of an 
enzymatically active A-subunit and a homopentameric B-subunit.  Stx binds to cells expressing 
the glycolipid receptor, globotriaosylceramide (Gb3) through the B-subunit.  Following binding 
to Gb3 expressing cells, Stx is endocytosed.  In sensitive cells, Stx undergoes retrograde transport 
to the endoplasmic reticulum (ER) (73).  From the ER the A-subunit is able to reach the 
cytoplasm where it cleaves adenine 4324 in 28S rRNA, inhibiting protein synthesis (20).     
Neurological complications associated with HUS in humans include cortical blindness, 
irritability, lethargy, hemiparesis, seizure and coma (15,16).  Magnetic resonance images (MRIs) 
of individuals taken during STEC infection have observed symmetric hyperintensities that can 
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affect most structures within the brain (18).  Some hemorrhaging with random distribution 
throughout the brain has been observed in children who succumb to disease (114), however, 
microhemorrhaging and overt pathology are not observed in adult brains (189,190).  In the 2011 
German outbreak of Stx2a producing enteroaggregative E. coli O104:H4, there were an 
unusually high number of HUS cases (22%).  In addition to the high number of HUS cases, 
almost 50% of patients also had neurological symptoms (113).   
The role that Stx plays in progression to CNS dysfunction is not well understood.  Studies 
on humans are mostly conducted retrospectively or are postmortem making it difficult to 
determine the role of Stx during the course of disease.  While no current animal model 
recapitulates all aspects of human disease, mice challenged with Stx2a exhibit neurological 
symptoms similar to those seen in humans including lethargy, abnormal gait, hind-limb paralysis 
and seizures (115,116).   
In addition to targeting renal cells, studies have suggested that Stx targets the endothelial 
cells forming the blood brain barrier (BBB) (131,132).  The BBB is a specialized endothelium 
where the endothelial cells are capable of forming tight junctions, leading to reduced paracellular 
movement and high transendothelial electrical resistance (191,192).  It is a highly selective 
means to maintain homeostasis within the brain parenchyma and protect it from harmful 
components in the blood.  Damage to the BBB leaves the brain vulnerable to outside influences 
that can lead to dysfunction.  In order for Stx to directly damage endothelial cells and disrupt the 
BBB to gain access to the brain, it must be able to bind endothelial cells and be endocytosed.  To 
gain insight in to the role of microvascular endothelial cells as a target for Stx to access the brain 
we used primary and immortalized cell lines.  In this study, the Gb3 expression and susceptibility 
to Stx2a of microvascular endothelial cells from the mouse and human brain were examined. 
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Materials and Methods 
Shiga toxin. Stx2a was obtained from the Biodefense and Emerging Infectious Diseases 
Research Resources Repository (BEI, Manassas, VA).  Lipopolysaccharide (LPS) content was 
determined by the limulus amoebocyte lysate (LAL) assay (Lonza).   
 
Cell culture.  Human cerebral cortex microvascular endothelial cells (BMEC, ACBRI 376, Lot 
376.04.0H.0U.0Y) were obtained from Cell Systems Corporation (Kirkland, WA) and were 
propagated in Complete Classic Medium with serum, CultureBoost and Bac-Off
®
 antibiotic (Cell 
Systems, Kirkland, WA).  Cells were harvested with the Passage Reagent System (Cell System) 
according to manufactures protocol.  The BALB/c bEnd.3 cell line was a gift from Dr. Jerry 
Lingrel and was maintained in DMEM with 10% FBS and Pen/Strep.  Cells were also cultured in 
RPMI 1640 medium containing 10% heat inactivated fetal bovine serum (HIFBS, Gibco, Life 
Technologies), 10% Nu-Serum (Corning, Fisher Scientific), 2 mM L-glutamine (Hyclone, Fisher 
Scientific), 1 mM sodium pyruvate (Hyclone), 1.0 U/ml MEM non-essential amino acids 
(Gibco), 1.0 U/ml vitamins (Gibco) and 100 U/ml Penicillin-100 µg/ml Streptomycin solution 
(Hyclone) when indicated. 
 
Toxicity assay.  Stx was serially diluted in 20 µl of medium in sterile, black, clear, flat-bottom 
96-well plates (Corning, Tewksbury, MA).  Cells (in 60 µl of medium) were added to toxin-
containing wells at subconfluent or confluent numbers, as indicated in cells per well, and were as 
follows for each cell type:  
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                           TABLE 3.1.  Plating densities for brain endothelial cells. 
Cell Type Subconfluent (cells/well) Confluent (cells/well) 
bEnd.3 6 x 10
3
 1.2 x 10
4
 
BMEC 1.5 x 10
3
 8 x 10
3
 
 
 
 Toxin-treated cells were incubated at 37
o
C in 5% CO2.  After 42 h the medium was removed 
and 50 µl of fresh medium containing 10% (vol/vol) alamarBlue (AbD Serotec, Raleigh, NC) 
was added.  Cells were incubated in the presence of alamarBlue for a total of 3 h.  Fluorescence 
was read at 590 nm on a FLX-800 fluorimeter (BioTek, Winooski, VT) every 30 min and values 
within the linear range, before depletion of substrate, have been reported.  In assays using TNF-
α, cells were plated at the subconfluent or confluent densities in 60 µl of medium and incubated 
overnight.  TNF-α (10 ng/ml) was added the next day and 24 h later toxin was added.  Cells were 
incubated for an additional 42 h and analyzed as described above.  Dose-response curves were 
plotted as the percent relative fluorescence units (RFU) of untreated cells verses toxin 
concentration.   
 
Flow cytometry to detect Gb3.  5 x 10
4
 cells were cooled on ice for 30 min and all subsequent 
incubations were carried out on ice.  Cells were incubated for 1 h with antibody to Gb3 (clone 
38-13, Accurate Chemical & Scientific Corporation, Westbury, NY) or PBS for controls.  Cells 
were washed, incubated for 1 h with fluorescein isothiocyanate (FITC) conjugated α-rat IgM 
secondary antibody diluted 1:500 (AbD Serotec, product number MCA189F, Bio-Rad, Raleigh, 
NC) and analyzed by flow cytometry (BD FACSCalibur; Becton Dickinson, Franklin Lakes, 
NJ).  Due to the limited number of cells, analysis was performed by collecting 1 x 10
4
 events or 
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all events collected for 5 minutes. Unstained cells (for labeled primary antibody) or cells 
incubated with secondary antibody (for unlabeled primary antibody) were used as negative 
controls.  Cells were gated for the live cell population based on the forward and side scatter.   
 
Pretreatment with TNF-α.  To assess the role of TNF-α on Gb3 expression, cells were plated in 
12-well plates and allowed to adhere overnight.  TNF-α (10 ng/ml) was added and 24 h later 
cells were harvested and treated as described above.  As a positive control for TNF-α activity, 
stimulated BMECs were stained for induction of ICAM-1 expression and analyzed by flow 
cytometry.  Allophycocyanin (APC) labeled ICAM-1 (CD54) antibody was diluted 1:200 (clone 
HA58, product number 353111, BioLegend, San Diego, CA).  
 
Statistical analysis.  Statistical analysis for flow cytometry was performed by unpaired 
Student’s t-test using Prism5 (GraphPad Software, La Jolla, CA). 
 
 
Results 
Toxicity of Stx2a to cerebral microvascular endothelial cells. 
 Neurologic symptoms, including lethargy, irritability, cortical blindness, and seizures, are 
often observed in human hemolytic uremic syndrome, due to infection by Shiga toxin producing 
E. coli (15,16,18).  In addition, mice injected with purified Shiga toxin often display hind-limb 
paralysis and seizures (115).  However, it is unclear what cells in the brain are targeted in 
disease.  To determine if susceptibility of microvascular endothelial cells from the brain of mice 
and humans mediates sensitivity to Stx2a, we tested an immortalized line, bEnd.3, from BALB/c 
mice and primary human microvascular endothelial cells isolated from the cerebral cortex.   
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Cell were incubated with 10-fold dilutions of purified Stx2a, ranging in concentration 
from 0.5 to 5 x 10
-6
 µg/ml for bEnd.3 cells or 0.5 to 5 x 10
-7
 µg/ml for BMECs.  After a 42 h 
incubation with Stx2a, the metabolic activity was assessed by the reduction of resazurin to the 
fluorescent resorufin.  No loss of metabolic activity was seen, suggesting neither the bEnd.3 
immortalized line nor the primary human BMECs were susceptible to Stx2a. Additionally, the 
level of confluence of the cells did not have an effect on susceptibility (Figure 3.1A and 3.1B).   
Previous studies reported pre-treatment with TNF-α sensitized cells to Stx2a 
(131,132,165).  Pre-incubation of human BMECs with TNF-α (10 ng/ml) did not sensitize the 
cells to the effects of the toxin (Figure 3.1B).  Adhesion molecules are upregulated on 
endothelial cells following exposure to pro-inflammatory cytokines, including TNF-α (193).  To 
confirm that the TNF-α was active, BMECs were stained for ICAM-1 following incubation with 
TNF- for 24 h and upregulation of the cell surface expression of ICAM-1 on BMECs was 
observed (Figure 3.2).  
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Figure 3.1.  Metabolic activity of Stx2a-treated cerebral cortex microvascular endothelial 
cells.  (A) bEnd.3 immortalized cerebral cortex microvascular endothelial cells and (B) primary 
human cerebral cortex microvascular endothelial cells were incubated with Stx2a for 42 h.  The 
toxin containing media was removed and fresh media containing 10% alamarBlue was added.  
Cells were incubated for an additional 3 h and the fluorescent reduction of alamarBlue was 
measured every 30 min.  The 1 h time point is shown except for subconfluent BMECs which 
depicts the 3 h time point.  Graphs depict toxin-treated cells as a percent of untreated control 
cells.  Results are the average of three individual experiments and error bars correspond to 
standard deviation of the mean.  
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Figure 3.2.  Upregulation of surface ICAM-1 on BMECs following stimulation with TNF-α.  
BMECs were incubated with 10 ng/ml TNF-α for 24 h and then stained for surface expression of 
ICAM-1 (CD54).  ICAM-1 staining was analyzed by FACS.  Results depict a single trial. 
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Gb3 expression on cerebral cortex endothelial cells. 
 The level of receptor expression is suggested to affect the susceptibility of cells to Stx 
(132,165).  Flow cytometry was used to determine if both the mouse and human cells were 
resistant to the effects of Stx due to a lack of Gb3 receptor expression.  For the bEnd.3 cells, 
equivalent staining was seen in the presence or absence of the primary antibody to Gb3, 
suggesting the mouse cells lacked expression of Gb3 (Table 3.2).  Slightly increased values of 
the geometric mean fluorescence were observed for the human BMECs both without and with 
TNF-α stimulation, however these values failed to reach significance (p=0.0538 and p=0.1486 
respectively) (Table 3.2).   
In a previous study using primary human BMECs, Bauwens et al. reported that the 
microvascular endothelial cells they isolated from human cerebral cortex were susceptible to 
Stx1 and Stx2a, as assessed by crystal violet staining, without the use of sensitizing agents such 
as TNF-α (133).   While our studies used the medium recommended by the manufacture, 
Bauwens and colleagues used enriched RPMI 1640 medium to propagate their BMECs.  To 
evaluate whether media played a role in altering levels of Gb3 expression and susceptibility, we 
cultured both the bEnd.3 and human BMECs in the medium used in their study.  The human 
BMECs grew too poorly in the RPMI 1640 medium to assess sensitivity to Stx2a or Gb3 
expression.  The bEnd.3 line grew in the RPMI 1640 medium; however the media had no effect 
on the Gb3 expression of these cells (Table 3.2).   
 
 
 
 
 
64 
 
 
 
TABLE 3.2.  Cell-surface Gb3 on cerebral cortex microvascular endothelial cells. 
Cell Type                                                      Geometric Mean of the Fluorescent Intensity 
                                                                          2
o
 ab Alone                                      Gb3                                         
bEnd.3 grown in DMEM                                 12.1 ± 0.4                                    12.4 ± 0.1 
bEnd.3 grown in RPMI 1640                           10.6 ± 0.2                                    10.8 ± 0.1 
BMEC                                                              16.4 ± 1.4                                    18.7 ± 0.5 
BMEC treated with TNF-α                              16.4 ± 2.1                                    20.7 ± 1.7 
Results are reported as average and standard deviation for three experiments, except BMEC 
treated with TNF-α (n=2).  Results have been gated for live cells. 
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Discussion 
The brain is protected primarily by the specialized endothelium that makes up the blood-
brain barrier (BBB).  The endothelial cells of the BBB differ from those of most other 
vasculature by the formation of tight junctions between cells to reduce the ability of molecules to 
pass paracellularly.  Brain endothelial cells could serve either as a target for Stx, or as a barrier 
preventing access to susceptible cells.   
In order for brain endothelial cells to be a target of Stx and directly damaged, the toxin 
must be able to bind the cells via its glycolipid receptor, Gb3, and be endocytosed.  Consensus in 
the literature exists that murine renal endothelial cells do not express Gb3; however there are 
conflicting results for the endothelial cells of the brain.  While multiple groups have reported that 
murine brain endothelial cells do not express Gb3 (115,194), Okuda et al. described Gb3 staining 
within the cortex and pia matter of wild-type mice which they suggested corresponded to 
endothelial marker CD31 staining, and this observed staining was absent in their Gb3 knockout 
animals (26).  However, the Gb3 staining, assessed by immunohistochemistry with a monoclonal 
antibody, in their brain sections was very limited making it difficult to determine if the staining 
was truly marking endothelial cells.  Kolling et al. showed that false positive staining for Gb3 
occurred when tissues were immersion fixed using ethanol to dehydrate instead of acetone, and 
false positive staining was not observed in tissues that were fixed by perfusing the animal (195).   
Okuda et al. did not report using perfusion to fix their tissues, but only that they were fixed in 
formalin and embedded in paraffin (26).   In addition, studies using iodine
125
 labeled Stx1 and 
Stx2a found that 1 h following injection in mice, neither Stx1 nor Stx2a deposited in the central 
nervous system or brain stem of the animals (55).  However, at 48 h Stx2a, but not Stx1, was 
detected in the brain (56).  These results suggest a lack of immediate binding of Stx2 to 
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endothelial cells, although over time Stx2 can access the brain tissues.  In this study, our results 
for bEnd.3 cells were in agreement with the majority that murine microvascular endothelial cells 
do not express Gb3.  Additionally, the lack of Gb3 expression explains the lack of sensitivity of 
brain endothelial cells to Stx2a.   
While Gb3 knockout mice were completely rescued from Stx mediated death (26), 
Porubsky et al. have reported that approximately 65% of mice with Gb3 expression only knocked 
out in renal tubule cells still succumb to neurological complications (176).  However, when Gb3 
is knocked out in both renal tubule cells and endothelial cells, survival is only increased by 
approximately 25%.  Therefore, there is still a pool of Gb3 expressing cells that play a significant 
role in Stx mediated complications and death.   
Fujii et al. have shown that the Gb3 synthase gene, α1,4Gal-T, is expressed in the murine 
brain (196).  Neurons from multiple regions within the brain have been found to express Gb3 and 
are implicated as targets of toxin (115,197,198).  Obata et al. observed Gb3 positive motoneurons 
that were also labeled with Stx2a in treated mice (115).  In addition to motonerurons, neurons 
within the olfactory bulbs, cerebral cortex, hippocampus, striatum, amygdale, cerebellum, 
hypothalamus, thalamus and medulla oblongata stain positive for Gb3 (197).   
There are additional cell types in the mouse brain which react to Stx challenge, although 
if it is a direct or secondary response is not clear. Ultrastructural studies of mouse and rat brains 
following Stx treatment have shown damage to neurons including demyelinated axons, 
cytoplasmic edema and degenerative phenotypes (115,116,198).  Stx2a has been found in 
reactive astrocytes of rat brains treated through intracerebroventricular administration (199).  
However, mouse astrocytes were reported to lack Gb3 expression, though they exhibited a 
reactive phenotype with severe swelling and cellular breakdown in Stx challenged animals 
67 
 
(115,116).  Tironi-Farinati et al. found the integrity of oligodendrocytes to also be compromised 
after sub-lethal toxin challenge causing loss of myelin, however Gb3 or toxin labeling of these 
cells was not performed (116).   
Additionally, in studies of mice challenged with Stx2a we have observed metabolic 
changes in the brain through non-invasive magnetic resonance spectroscopy (MRS) (163).  
Levels of phosphocreatine, a high-energy phosphate donor, are reduced in Stx2a treated animals 
indicating increased metabolic activity.  This observed increase in metabolism is correlated with 
an increase in activated microglial cells also seen in Stx2a treated mice (unpublished data).  
Microglial cells constitute a form of macrophage within the brain that are activated rapidly in 
response to brain injury or damage (200).  Interestingly, in two separate studies in toxin treated 
animals, a lamellipodia-like projection from either reactive astrocytes or glial cells was observed 
interrupting the pre- and post-synapses of neurons.  It has been suggested that these projections 
may be physically blocking excess neurotransmitter release, specifically glutamate, thereby 
protecting neurons (115,116).   
Taken together, it is unlikely that murine brain endothelial cells are the direct target of 
Stx.  As the major cell type exhibiting Gb3 expression in the brain, neurons appear to be the most 
likely targets of Stx within the mouse brain.  Dysfunction of various types of neurons, including 
the motorneurons, can account for some of the deficits seen in Stx challenged animals.  Other 
cell types are reactive to toxin challenge, which may play a role in increasing CNS dysfunction; 
however, they either lack Gb3 expression or expression levels have not been measured so a direct 
interaction with Stx is unknown at this point.  
Given that following challenge with Stx symptoms associated with CNS pathology are 
observed, but endothelial cells are not targeted, then the BBB must be breached another way for 
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toxin to access the brain.  It is likely that inflammation plays a significant role in the loss of 
integrity of the BBB.  Inflammation, both local and peripheral, has been found to increase the 
permeability of the BBB (201,202).  While lipopolysaccharide (LPS) associated with Gram 
negative bacteria is capable of inducing inflammation through the Toll-like receptor 4 pathway 
(203), CNS symptoms are observed in mice challenged with toxin lacking LPS,  indicating that 
Stx itself is capable of inducing an inflammatory response in vivo.  This is supported by studies 
showing that Stx can induce the production of pro-inflammatory cytokines including TNF-α and 
IL-6 from murine macrophages (204).  TNF-α, IL-1β and IL-6 are cytokines that are capable of 
passing through the BBB and can weaken the BBB by reducing the trans-endothelial electrical 
resistance of the endothelial cell tight junctions (205).  In addition, these pro-inflammatory 
cytokines are capable of inducing the release of additional cytokines and inflammatory mediators 
from glial cells within the brain, further promoting an inflammatory environment (206,207).  In 
mice challenged with Stx, significant levels of edema are often observed in the brain parenchyma 
indicative of an inflammatory response (115,116).  Additionally, a study by Pinto et al. showed 
that treatment of mice with the anti-inflammatory drug, dexamethasone, increased the integrity 
of the BBB, protected neurons and reduced reactive astrocytes (208) supporting a role for 
inflammation in leading to BBB breakdown and CNS dysfunction.  
Changes in the mouse brain in response to Stx2a challenge are similar to what is 
observed in human neurologic disease following STEC infection.  Similar to the predominant 
symptoms of mice, humans frequently exhibit lethargy, cortical blindness, changes in behavior 
and hemiparesis (15,16,18).  Additionally, seizure activity and coma are the most severe 
symptoms often observed in human disease and a proportion of mice have been reported to have 
seizure activity (115).  As with the mouse brain, in order for Stx to directly disrupt endothelial 
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cells and the BBB in humans it must bind Gb3 and gain entry.  In contrast to murine brain 
microvascular endothelial cells, human BMECs are suggested to have low levels of Gb3 as 
identified predominantly by glycolipid extractions of cells and toxin binding overlays (130,131). 
In this study we were only able to detect low, but not statistically significant levels of Gb3 
expression on human BMECs using flow cytometry.     
The published literature differs on the inherent sensitivity of human BMECs.  A number 
of studies, including those using commercially available cells, have reported BMECs to be fairly 
resistant to Stx (131,132,165,209).  On the other hand, studies which share a similar method of 
isolating and culturing BMECs have reported these cells to be sensitive to toxin at much lower 
doses (133,164).  For this study our cells were obtained commercially from Cell Systems 
Corporation.  These cells were not sensitive to Stx2a, similar to the results obtained for other 
commercial BMECs.  One of the major differences between the commercially available cells and 
the cells isolated by individual investigators was the media the cells were cultured in (a heavily 
supplemented RPMI 1640 media).  In this study we addressed if the media had an effect on 
BMECs.  bEnd.3 immortalized mouse endothelial cells grew in the supplemented RPMI 1640 
media and exhibited no increase in Gb3 content.  However, when cultured in the RPMI 1640 
media, BMECs from Cell Systems grew poorly.  The cells shrunk and lifted off from the culture 
dish.  The inability to grow the commercial BMECs in the media used for the isolated BMECs 
suggests that there may be a difference in the cells isolated.      
Within the brain, human neurons have been found to express Gb3 (115,189).  An increase 
in Gb3 expression on neurons was observed postmortem within the brains of patients who 
succumb to disease (189).  In addition to changes in neurons, human astrocytes have been shown 
to upregulate Gb3 in response to IL-1β in culture (210).  Interestingly, IL-1β was found to be 
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increased in neurons and the frontal cortex in adult brains on autopsy and a minor increase in 
activated microglia was also observed (189).   
 Inflammation is also suggested to play a major role in human CNS dysfunction.  
Elevated levels of pro-inflammatory cytokines TNF-α and IL-6 have been observed in patients 
with HUS (184) and high plasma levels of IL-6 were found in a set of HUS patients that 
exhibited CNS dysfunction (211).  Human macrophages have also been shown to release pro-
inflammatory cytokines in culture in response to Stx (212).  Edema within the brain has been 
observed by MRI and postmortem autopsy in many pediatric cases (16,114).  In addition, pro-
inflammatory cytokines TNF-α and IL-1β have been suggested to upregulate expression of Gb3 
on BMECs in vitro, increasing their sensitivity to toxin (132,165).  Contrary to this, we were 
unable to increase the Gb3 expression of BMECs or their sensitivity to Stx2a using TNF-α in this 
study.  Variability is often observed from donor to donor when using primary cells and has been 
observed in studies of primary HUVECs and GMECs (122,129).  Interestingly though, no 
increase in Gb3 expression on endothelial cells was observed in autopsied brains of a group of 
individuals who succumbed to complications (189).   
In summary, the mouse model of challenge with Stx2a shares similarity with human 
disease.  Although Stx appears to be able to cross the BBB and cause dysfunction in the brains of 
mice and humans, as we have shown here it does not appear to be through direct toxicity to 
microvascular endothelial cells.  While inflammation may play a role in weakening the BBB, the 
direct targets of toxin within the brain and the manner in which Stx induces dysfunction requires 
further investigation. 
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Chapter IV 
 
 
 
siRNA Screen to Identify Novel Components of the Cell Utilized by Shiga 
Toxin   
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Abstract 
Shiga toxin (Stx) is the main virulence factor of Shiga toxin-producing Escherichia coli (STEC).  
Stx, an AB5 toxin, consists of an enzymatically active A-subunit that can cleave rRNA, 
inhibiting protein synthesis, and a homopentameric B-subunit that binds to cells.  Infection with 
STEC can lead to the life-threatening condition hemolytic uremic syndrome.  After being 
endocytosed, Stx undergoes retrograde transport to the endoplasmic reticulum from which the A-
subunit translocates to the cytosol.  While the trafficking pathway for Stx has been the focal 
point of many studies, most have used cell lines that are not applicable to the target organs of 
HUS.  In order to better understand the mechanism of Stx in vivo, it is important to study Stx in 
the context of cells that are known to play a role in disease.  In this study, the trafficking pathway 
of Stx in primary human renal proximal tubule epithelial cells was characterized using a genome 
wide siRNA screen.  Genes that were identified in the screen as being important for Stx 
trafficking included both genes whose involvement has been previously described in other cell 
types and some novel cellular components.  
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Introduction 
 Shiga toxin-producing E. coli (STEC) are a major source of food-borne illness causing 
approximately 265,000 cases of disease each year in the United States alone (1).  The primary 
virulence factor of STEC is the AB5 toxin, Shiga toxin (Stx).  The A-subunit of Stx has N-
glycosidase activity by which it causes the inhibition of protein synthesis (20), while the B-
subunit is a homopentamer that binds the toxin to its cellular receptor, globotriaosylceramide 
(Gb3) (213).   
 Gb3 is a glycolipid made up of the carbohydrate moiety Galα1-4Galβ1-4Glc and a 
ceramide tail.  Upon engagement by the binding of Stx, Gb3 clusters in detergent-resistant 
membranes known as lipid rafts, from which endocytosis occurs (50,64).  Endocytosis of toxin 
occurs by both clathin-dependent and clathrin-independent methods and has been shown to 
require signaling at the membrane in order to proceed (65,66,68).  Following endocytosis, the 
current understanding of Stx retrograde transport is that it traffics from early and recycling 
endosomes to the trans-Golgi network (TGN) and then from the TGN Stx reaches the 
endoplasmic reticulum (ER) (73).  At a point either within the endosome or TGN, the Stx A-
subunit is nicked by the endoprotease furin to create an A1 and A2 fragment.  Furin cleavage 
results in the catalytic A1 fragment consisting of residues 1-251 (approximately 27.5 kDa) and 
the B-subunit associated A2 fragment consisting of residues 252-293 (approximately 4.5 kDa) 
(75).  The A1 and A2 fragments remain associated during trafficking to the ER by a disulfide 
bond between Cys242 and Cys261 in the respective fragments (35,76).  Upon reaching the ER, 
the disulfide bond between the fragments is reduced and the A1 fragment is released while the 
A2 fragment remains associated with the B-subunit.  From the ER, the A1 fragment translocates 
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to the cytosol where it cleaves adenine 4324 in the 28S rRNA, inhibiting protein synthesis within 
the cell (20). 
 Approximately 90% of cases of STEC infection resolve without complication, however 
the remaining 10% progress to more severe disease including the life-threatening condition, 
hemolytic uremic syndrome (HUS) (155).  The most prominently recognized target organ of 
HUS is the kidney.  Within the kidney multiple cells are damaged during the course of disease 
including glomerular epithelial and endothelial cells (103,125) and renal tubule epithelial cells 
(176).  Renal tubule cells, in particular proximal tubule cells (RPTECs), express high levels of 
Gb3 and are highly susceptible to Stx in vitro (29,170).  In addition, renal biopsies during the 
acute phase of disease have shown damage to RPTECs including loss of the brush borders, cell 
flattening and vacuolization (176).  Porubsky et al. showed that knocking out Gb3 expression in 
the renal tubules of mice protected the renal epithelium from Stx2 toxicity (176) confirming the 
importance of tubule epithelial cells in the pathology of HUS. 
 There are currently no treatment options for HUS, other than supportive care, and many 
antibiotics are not recommended as they have been shown to increase toxin production (39,162).  
The trafficking pathway necessary for Stx to reach the cytosol provides steps which can be 
targeted to block the entry and transport of Stx.  Currently, most of our knowledge of Stx 
trafficking comes from studies in immortalized cell lines such as the cervical cancer epithelial 
line, HeLa, which has no direct link to organ systems targeted during disease.  Additionally, 
many of the cell types used in previous trafficking studies are relatively insensitive to Stx and 
some required treatment with butyric acid to increase sensitivity (66).  It is unknown if the 
trafficking pathway differs in highly susceptible, in vivo target cells.  To gain a better 
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understanding, we investigated the trafficking of Stx2a in primary RPTECs using a genome wide 
siRNA screen.   
 
 
Materials and Methods 
 
Primary Cells.  Human renal proximal tubule epithelial cells (RPTECs) from a 7-year-old male 
(8F3151) were obtained from Clonetics (Lonza, Walkersville, MD) and maintained at 37
o
C in 
5% CO2  and RenalLife complete medium (Lifeline Cell Technology, Walkersville, MD).  Cells 
were harvested with TrypKit (Lifeline Cell Technologies, Walkersville, MD) according to 
manufactures protocol.   
 
Stx supernatant.  Overnight cultures grown in cation stabilized Mueller-Hinton broth (Difco) 
were diluted 1/100 in fresh broth and grown at 37
o
C with shaking to an optical density at 600 
nanometers of approximately 0.5.  Ciprofloxacin was added at 10 ng/ml and cultures were grown 
overnight.  Cultures were centrifuged, filter sterilized and the toxin-containing supernatant was 
collected. 
 
Transcriptional Analysis.  RPTECs (5 x 10
4
) in complete media were incubated with Opti-
MEM (Gibco, Life Technologies, Carlsbad, CA) or Opti-MEM and diluted INTERFERin
®
 
(Polyplus Transfection) for 72 h.  Cells were harvested and RNA was extracted using a RNeasy 
kit (Qiagen, Valencia, CA) according to manufactures protocol.  RNA samples were processed 
by the Gene Expression Core at Cincinnati Children’s Research Hospital (Cincinnati, OH).  
Briefly samples were labeled by WT Ovation Pico WTA and WT Ovation Exon Module 
(NuGENE, San Carlos, CA).  Samples were arrayed on a GeneChip
®
 Human Gene 1.0 ST Array 
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(Affymetrix, Santa Clara, CA) and results were normalized using Robust Multi-array Average 
(RMA). 
   
siRNA library.  A siRNA screen of the human genome was performed to identify cellular 
factors necessary for Shiga toxin to exert its toxic effect.  A library containing 21,121 siRNA 
pools ((Dharmacon, Thermo Fisher Scientific, Waltham, MA, Lot #050915) with 4 target 
sequences per pool and separated into sub-libraries (the Human Genome (G-005000), Human 
Druggable (G-004600), Human Protein Kinases (G-003500) and Human GPCR (G-003600)) 
was assayed.  The lyophilized library was provided in a 96-well format.  Library plates were 
thawed, centrifuged briefly and resuspended with 1x siRNA buffer (Dharmacon) using the 
Agilent Bravo Automated Liquid Handling Platform (Agilent Technologies, Santa Clara, CA).  
Plates were mixed on a plate shaker for 30 min at room temperature.  siRNAs were step diluted 
to a final concentration of 200 nM and 2 µl aliquots were dispensed to 384-well black, clear 
bottom microtiter plates (Greiner Bio-one, Monroe, NC).  Plates were sealed and stored at -20
o
C 
until use. 
 
siRNA screen.  siRNAs at a final concentration of 5.9 nM were transiently transfected in to 
RPTECs using a reverse transfection protocol.  Briefly, the 384-well microtiter plates containing 
2 µl of 200 nM stock siRNAs were thawed and 14 µl Opti-MEM was added using the 
Multidrop
TM
 Combi Reagent Dispenser (Thermo Fisher Scientific).  INTERFERin
®
 was diluted 
10-fold in sterile water (Gibco, Life Technologies) and 2 µl per well was dispensed into the 
siRNA plates from the master plate, with mixing, using the JANUS Automated Workstation 
liquid handler (Perkin Elmer, Waltham, MA).  After a 10 to 30 min incubation at room 
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temperature, 2 x 10
3
 cells in 50 µl of media were added to each well using the Multidrop
TM
 
Combi.  Plates were incubated at 37
o
C in 5% CO2.  Approximately 48 h after transfection, the 
media was removed with a plate washer (BioTek ELx405) and 50 µl of fresh media was 
dispensed using the Mutlidrop
TM
 Combi.  After 24 h, Stx2a was diluted in complete media and 
0.03 ng was added per well in 20 µl.  Metabolic inhibition was less than expected for the first set 
of plates tested, therefore toxin was increased to 0.06 ng per well in 20 µl for all the subsequent 
plates.  Approximately 42 h later media was removed with a plate washer and replaced with 
fresh media containing 10% alamarBlue (AbD Serotec).  Plates were returned to 37
o
C and the 
reduction of resazurin to resorufin proceeded for approximately 5.5 h.  Fluorescence was read on 
an EnVision Multilabel Plate Reader (Perkin Elmer, Waltham, MA) at 535 nm excitation and 
590 nm emission.  The metabolic activity of cells receiving both siRNA and Stx was compared 
to that of cells not receiving siRNA or Stx (cells alone).   
 
                        
                       
       
 
Controls on each plate included a non-targeting siRNA, CASP8 and FADD-like apoptosis 
regulator (CFLAR) siRNA Smartpool (Dharmacon) and a column not receiving INTERFERin
®
.  
Non-targeting siRNA was a scramble sequence that should not be specific to any gene.  CFLAR 
was a known single gene whose knockdown should cause loss of cell viability if the siRNA was 
complexed correctly with the transfection reagent and delivered to the cell.  Cells not receiving 
INTERFERin
®
 allowed for assessment of any reagent specific toxicity to cells and its absence 
from CFLAR ensured that siRNA required complexing with the reagent to affect cell viability. 
The full genome screen was run once and was conducted in the Biosafety level 3 (BSL3) facility 
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at the University of Cincinnati (Cincinnati, OH) in collaboration with the Air Force Research 
Laboratory, 711
th
 HPW/RHPCB.  
 
Results and Discussion 
Transcriptional analysis of RPTECs.   
Transfection reagents can cause toxicity and off target effects to cells.  The effect of 
INTERFERin
®
, the siRNA transfection reagent chosen for the genome screen, on the primary 
RPTECs was assessed by comparing the transcriptional profile of cells treated with and without 
reagent.  Cells were treated with INTERFERin
®
 or media alone for 3 days after which RNA was 
extracted and subjected to transcriptional analysis using an Affymetrix Human Gene 1.0 ST 
Array.  Treatment of RPTECs with INTERFERin
®
 did not alter global transcription of the cells 
(Figure 4.1A) or the transcription of the top candidate genes (Figure 4.1B). 
 
siRNA screen. 
To determine the cellular components necessary for Stx to exert its effects, we developed 
a genome wide siRNA screen.  We chose to use human primary renal proximal tubule epithelial 
cells (RPTECs) for the screen since they are sensitive to toxin and a target in vivo during the 
course of human disease (176).  The siRNA library contained siRNA pools directed against 
known human genes.  The metabolic activity of cells receiving siRNA and toxin were compared 
to those receiving only toxin or cells alone.  siRNA pools were labeled as rescuing from Stx if 
they resulted in a metabolic activity that was greater than cells receiving only Stx.  A total of 
2916 genes were identified.  The siRNAs designated as rescuing were ordered based on 
metabolic activity as a percent of the activity of cells alone.  For siRNAs that resulted in a 
metabolic activity 90% or greater than cells alone, 517 genes were identified (listed in Table 4.1) 
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and will be referred to as top candidate hits.  Genes listed in Table 4.1 were the result of a single 
screening of the genome library.   
Among the top candidate hits, we identified genes previously associated with Stx 
including proteins required for intracellular trafficking of Stx (clathrin heavy chain (CLTC) and 
dynamin (DNM2) (69)), as well as proteins required for signal transduction (sterile α-motif and 
leucine zipper containing kinase (ZAK) (23)).  Identifying genes whose association with Stx has 
already been validated supports the power of this screen to successfully identify novel cellular 
components utilized by Stx.   
It has been established that siRNAs can have either activating or toxic effects on cells.  A 
siRNA that activates metabolism independent of Stx-mediated-inhibition would generate a false 
positive; similarly a siRNA that inhibits metabolism as well as protecting from Stx would be a 
false negative.  Therefore, in order to rule out false positives or negatives a screen would need to 
be run in the absence of toxin, to ascertain the effect of the siRNA alone on cellular metabolism.  
We were unable to run these additional screens to determine false positives among our top 
candidate hits; therefore, instead we analyzed the top candidate hits by looking for pathway 
enrichment.  If multiple components fell in to the same pathway it strengthens the individual 
genes and suggests that the identified pathway is likely involved in Stx trafficking.   
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Figure 4.1.  Transfection reagent INTERFERin
®
 does not affect transcription of primary 
RPTECs. (A) Global transcriptional profiling comparison of RPTECs alone to RPTECs treated 
with the siRNA transfection reagent INTERFERin
®
.  (B) Transcriptional profiling comparison of 
top candidate hits identified in the siRNA screen.  Microarray values are on a log2 scale. 
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Table 4.1.  Top candidate hits for siRNA screen in primary renal proximal tubule epithelial cells. 
 
LOC388073 
LOC400512 
CCDC51 
LOC390020 
POLL 
LOC441165 
NTHL1 
LOC391705 
ELL3 
RPN1 
OMD 
PAPPA 
SULT1A3 
LOC339451 
LOC387754 
ECGF1  
LOC391362 
INTERSEX 
RPS12P4 
ZNF561 
FUNDC2P2 
TEX41 
LOC84661 
NEDD8 
RP11-262K1.1 
UBE2J2 
REPS1 
FAM83C 
RHBDD2 
PTPN2 
LOC389628 
GARS 
ASMTL 
LOC402625 
SMIM3 
LOC388229 
TSG101 
LOC387886 
FLJ42351 
ANKRD20A18P 
DNAJB8 
C17ORF70 
LOC402681 
LOC392762 
BAGE 
LOC390231 
RETNLB 
C6ORF48 
OCEL1 
GYG 
MAST4 
LOC391360 
UCN3 
CUL3 
MAP9 
CCDC42B 
KRTAP5-2 
LOC402123 
NR0B2 
LOC400304 
LOC401463 
DCAF15 
FAM175A 
GTPBP3 
MRPL2 
LOC389149 
LOC400985 
LOC391707 
ZNF180 
LOC339903 
LIN54 
RPS15P4 
LOC391012 
LOC401034 
ZNF44 
PPP1R14A 
WBSCR23 
RHCG 
PLA2G5 
B3GNT4 
TMC7 
UCHL1 
RPL22 
LOC388937 
LOC400299 
KIF22 
LOC388006 
COL27A1 
FAR2P1 
COQ10B 
KIFC3 
LOC401038 
LOC388365 
LOC390533 
CGI-49 
ACBD4 
VLDLR 
ACTR1B 
ZNF135 
LOC401053 
LOC285442 
LOC401056 
LOC391594 
C20ORF144 
LIX1 
PALM 
DPP10-AS1 
LOC388509 
ZAK 
CRYGS 
ZNF616 
LOC401128 
LOC388849 
CDKN2A 
LINC00642 
PTGDS 
PANK2 
LOX 
GNB2L1 
RAB27B 
LOC388231 
MTERF4 
RNF183 
LOC402632 
CHCHD4 
LOC401054 
TP53 
LOC400948 
NIM1K 
LOC388573 
SEC24A 
SYNPR 
LYPD6B 
CYP2A6 
PDCL2 
PPME1 
LOC401126 
LOC401460 
TTPAL 
HMGN5 
ZNF251 
HPS5 
ZFR 
ZC3H10 
LOC400987 
LOC400937 
LOC387832 
STARD13 
LOC391373 
LOC389129 
LOC390688 
ENPP7 
LINC00517 
C6ORF106 
PPP4R1L 
MSANTD2 
IRX3 
FYCO1 
LOC400988 
COBLL1 
LOC389665 
HIST1H2AE 
LOC402072 
PYROXD1 
LOC388507 
SRPK1 
LOC339674 
LOC391003 
LOC388173 
ZNF140 
LOC390547 
LOC345378 
FKBP2 
TMEM151A 
STAT1 
LOC401032 
THEM4 
PDE6G 
LYPD6 
LOC402103 
C12orf49 
LOC389108 
PDE9A 
UBA3 
TRIM4 
LOC390683 
TXNDC15 
C11orf70 
ZDBF2 
TRABD2A 
PREX2 
EMP1 
LOC402716 
LOC391253 
LOC402318 
SFTPB 
LOC387884 
TSGA2 
FLJ40712 
NRAS 
SLC25A35 
ARAP2 
LHFPL1 
FMNL3 
IRX6 
LOC128208 
LOC400992 
LOC113386 
LOC389055 
ZBTB21 
VIPAS39 
MCEE 
APH1A 
LOC390511 
LOC387994 
RANBP3L 
TMX3 
HRAS 
LOC339229 
RQCD1 
ZNF256 
TNFAIP3 
XPNPEP2 
CCDC62 
RTL1 
WRN 
NMT1 
PPP4R2 
STAR 
C5orf30 
SFTPC 
CDC20B 
ULBP2 
C2orf78 
CEP104 
FKBP1C 
LOC389085 
RRBP1 
LOC389099 
LOC391723 
OR12D2 
ZFP42 
SLIT2 
GBP1 
MAN1A1 
PON2 
SMYD4 
LOC391205 
AKT1S1 
POLR3GL 
KIF5A 
LOC399867 
ALKBH3 
TMEM150A 
LRRIQ3 
SLC30A2 
FLJ40160 
ZNF101 
FBXO36 
PHF20 
RNF213 
FSHR 
MC2R 
SLC39A13 
CAPN9 
UBE2V1 
TTC24 
OR10R2 
TLE6 
LOC283530 
TCTEX1D4 
VDR 
LOC391343 
COMMD2 
IRF3 
ZBTB26 
PLLP 
C1orf162 
HIST1H2BK 
ARFGAP2 
ABCD4 
LOC389506 
GFM1 
MRPS12 
LACTB 
LOC390940 
WDR25 
LOC400781 
TTC6 
ASB10 
RIT1 
SNX4 
PCYOX1 
ONECUT1 
BLOC1S4 
DOCK3 
LCE2A 
LOC375323 
GGT7 
SPACA4 
SLC25A40 
MAGEC1 
UGP2 
SH3TC2 
LOC388787 
BMF 
LIN28A 
FANCL 
CYP2A7 
LOC387939 
PNPLA1 
ZNF439 
IHH 
C1QL2 
CPN1 
CLTC 
DSTYK 
IRX1 
LOC199897 
SMC6 
COPS3 
LOC390535 
LOC388001 
TNFSF18 
LOC389663 
FAM3D 
LOC391445 
FLJ14107 
MST1 
CYP4F2 
CRP 
ASUN 
OR8K1 
LOC389765 
LOC401599 
MSANTD4 
LOC343854 
C20orf203 
HMGB3 
LOC400858 
LOC90520 
ATPAF1 
ORM1 
PM5 
PDSS1 
RLIM 
LOC389073 
MGEA5 
LOC401740 
NFKBIE 
TADA1 
CD53 
TTC8 
NLGN4Y 
LOC400690 
KRT31 
LOC402596 
LOC197135 
OAS2 
LOC96597 
REG3G 
LOC388496 
LOC284661 
HSPA8 
LOC387880 
LOC115749 
LOC391358 
STAT4 
SPA17 
KIF2A 
CSMD2 
ARHGEF25 
CD244 
SAA4 
LOC388019 
PPP1R14B 
OR4E2 
LOC388617 
CCDC14 
EPT1 
C9ORF89 
LOC388139 
LYPD2 
NUDT16 
SETD1A 
PCDHA8 
CFC1 
LOC127391 
KIAA1377 
UBAC2 
LOC389242 
COX5A 
LOC283663 
LOC401087 
UNC5A 
LOC389842 
LOC116166 
LOC391347 
IFNB1 
LOC388177 
C3orf36 
LOC400790 
POR 
LOC392748 
ZNF366 
LOC389212 
LOC388002 
LIG3 
TEX33 
CACHD1 
LOC400506 
PPIB 
LOC401101 
RDH11 
LOC341370 
LOC400010 
RGS7 
LOC388948 
LOC401070 
PARP11 
LOC161823 
USMG5 
LOC400258 
METTL9 
NAP1L2 
LOC220594 
IFT88 
NDUFV1 
KCNH1 
ANAPC7 
LOC388407 
NAAA 
B4GALT4 
LOC400726 
FAM106A 
LOC391123 
LOC392843 
LOC401220 
USP15 
LHFPL2 
LOC388790 
CYP1A2 
YBEY 
SGCZ 
TM9SF2 
LOC399888 
DSG2 
LOC163782 
LOC400212 
TNFRSF10A 
LOC389742 
ITGA4 
SOX17 
BAX 
GSTT1 
ABI2 
GUSBP4 
LOC402016 
LOC389168 
CSMD3 
CCDC176 
APOD 
UGCG 
LOC388823 
UBA6 
LOC400954 
LOC400128 
SLC25A5 
TRAF3 
BIRC6 
IL10 
STC1 
LOC400964 
CER1 
BEST3 
PIK3C3 
MACROD1 
EAF2 
LOC123688 
GIMAP6 
CNPPD1 
DCTD 
CELA2A 
DNM2 
LOC401358 
PPP1R3B 
LOC388215 
C1orf61 
DLD 
LOC402682 
LOC284001 
LOC402676 
ASB5 
UBL4 
BTBD8 
DKFZP434C0631 
ZFP67 
PRUNE 
LOC389137 
CXORF21 
LOC51249 
PLP2 
LOC388550 
LOC389335 
LOC400861 
PAEP 
LACTB2 
RPP21 
ZMYM2 
PRR15L 
ZMAT3 
LOC402098 
TBCEL 
ZFHX3 
OR10X1 
ARL8B 
LOC401106
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Pathway and gene ontology enrichment of top candidate hits. 
ToppGene Suite ToppFun (214) (Cincinnati Children’s Hospital Medical Center, 
Cincinnati, OH) is an analysis tool through which functional enrichment can be determined in a 
list of genes.  The results of our screen generated a list of genes that when depleted from the cell, 
rescued from Stx induced inhibition of cellular metabolism.  Therefore, these genes indicated 
potential components of the cell that are utilized by Stx to reach the ribosome and inhibit protein 
synthesis.  We utilized ToppFun to enrich for shared pathways or the gene ontology categories: 
molecular function, biological process and cellular components within the genes in our top 
candidate hits (Table 4.1).  Enriching our list of top hits in this way allowed us to assign genes to 
roles within the cell and explore their relevance to Stx intoxication.  Comparisons could also be 
made to previously identified genes within these categories.  Of the 517 top candidate genes 
submitted to ToppFun, 362 were recognized and used for enrichment. Because confirmation 
screening was not completed, low stringency (p<0.05, no correction factor) was applied to the 
enrichment.  Results of known and potentially novel genes for events involved in Stx 
intoxication are discussed further.   
 
Stx receptor expression - Glycolipid biosynthesis.   
The glycolipid, Gb3 (Galα1-4Galβ1-4Glcβ1-1Cer) is the cellular receptor for Stx (Figure 
4.2).  Gb3 is made through the sequential addition of sugar moieties to ceramide by multiple 
transferases.  The loss of function of these transferases or the ability to form ceramide would 
lead to loss of receptor expression and would be expected to inhibit the ability of Stx to bind to 
the cell.  The gene, UDP-glucose ceramide glucosyltransferase (UGCG), was identified as a top 
candidate hit.  UGCG catalyzes the addition of the initial glucose to ceramide making it the 
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essential first step leading to the production of a variety of glycolipids including Gb3.  The 
importance of UGCG in Stx toxicity has previously been demonstrated in a mouse model.  
Targeted deletion of UGCG from renal tubules fully protected the renal epithelium from Stx 
induced damage (176).   
 Cholesterol and lipid rafts play an integral role in signaling and vesicle trafficking for Stx 
(167).  Depletion of cholesterol or inhibition of glycospingolipid synthesis protects cells from 
Stx, with the latter inhibiting trafficking from early endosomes to the trans-Golgi network 
(TGN) (215,216).  Candidate hits associated with cholesterol or glycolipids, which are not 
involved in Gb3 synthesis, suggest roles in the formation of lipid raft components necessary for 
Stx trafficking.  Genes enriched in this group included B4GALT4, B3GNT4, GYG1, ENPP7 and 
STAR (Figure 4.2).     
 
Cell-surface signaling and endocytosis.  
 Subsequent to binding cells that express Gb3, Stx undergoes endocytosis (Figure 4.3).  
Stx is internalized through both clathrin-dependent (65,66) and clathrin-independent pathways 
such as caveolae dependent mechanisms and inducing membrane invaginations (68).  Dynamin 
is involved in multiple types of endocytosis and because of this it cannot be determined which 
form of endocytosis knockdown of DNM2 rescued from in our screen.    
The clathrin-dependent endocytosis of Stx requires the interplay of lipid raft dynamics 
and signaling molecules.  Stx binding induces clustering to lipid raft domains from which 
endocytosis can occur.  Tyrosine kinase activity is important for toxin entering through clathrin-
mediated endocytosis (217).  Different tyrosine kinases have been implicated in Stx endocytosis 
and may be cell type dependent.  In HeLa cells, Syk is required for clathrin-mediated entry of 
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Stx.  However, the reduction in endocytosis and transport of Stx was greater in HeLa cells when 
genistein, a general tyrosine inhibitor, was used than piceatannol, a specific Syk inhibitor, 
suggesting additional tyrosine kinases may be involved (70).  Stx has been associated with the 
Src-family kinase, Yes, in the human renal adenocarcinoma cell line ACHN (64) and caused an 
increase in the activity of Syk and Lyn in Burkitt’s B lymphoma Ramos cells (71,72).   
A role for Syk, Yes or Lyn in RPTECs could not be determined in our study.  The values 
for all three kinases were below that of cells and Stx alone which suggests that the siRNAs may 
have been toxic to RPTECs in our screen.  Other membrane signaling components important for 
Stx, in addition to those already identified, are likely.  Other genes enriched in signaling 
pathways included DLD, PAPPA and TP53.  The possibility of additional signaling components 
was supported by cross-linking studies performed by Shimizu et al. which showed that Stx1 and 
Stx2a associate at the membrane with unidentified 27 kDa and 40 kDa molecules (218).  The 27 
kDa interacting partner was also discovered in a separate membrane study with Stx1 (64).  The 
identity of these interacting partners may be among our top candidate hits (Figure 4.3).    
While Gb3 is the only current known receptor for Stx other surface co-receptors may be 
involved through signaling or sorting activities.  Integrins, including a hit candidate ITGA4, are 
highly glycosylated and as integral membrane proteins are in proximity for possible engagement 
and subsequent activation of signaling events (Figure 4.3).  Integrins and integrin signaling is 
known to be important for endocytosis via caveolae and lipid rafts (219,220).   
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Figure 4.2.  Top candidate hits for glycolipid biosynthesis.  Pathway enrichment for top 
candidate hits involved in glycolipid biosynthesis.  Genes corresponding to enriched pathways 
are listed.  Lipid rafts (represented by grey area) involved in Stx binding and trafficking are 
enriched in cholesterol (represented by yellow hexagons), sphingolipids (represented by 
connected lines with blue top), Gb3 (represented by connected lines with two open and one 
closed circle) and phospholipids (represented by connected lines with black top).  The cell 
nucleus is represented by the double circles.  
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Figure 4.3.  Top candidate hits for cell surface signaling and endocytosis.  Pathway 
enrichment for top candidate hits involved in the endocytosis of Stx and signaling events 
initiated at the cell surface.  Genes corresponding to enriched pathways are listed.  Endocytosis 
can be clathrin (represented in green) dependent or independent.  Endocytosis requires the 
activation of signaling events (represented by yellow stars) and can involve cell surface receptors 
(represented by red rectangles) and lipid rafts (represented by components in the grey area).   
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Intracellular trafficking of Stx.  
After undergoing endocytosis, Stx traffics from the endosome (Figure 4.4, step 1) to the 
TGN (Figure 4.4, step 2), the TGN to the endoplasmic reticulum ER (Figure 4.4, step 3), and 
then from the ER gains access to the cytosol (Figure 4.4, step 4).  The current paradigm in the 
published literature suggests that following endocytosis the retromer complex components SNX1 
and SNX2 are important for early endosome sorting (221,222).  Stx travels from EEA1 
expressing early endosomes to Rab11 expressing recycling endosomes (223) and then to the 
TGN.  Other important components identified in this Stx trafficking pathway include EpsinR 
(224), Rab6a’ (225), STX5 and STX16 (226,227), golgin-97 (228), golgin-245 (229), GCC185 
(230), GARP, Arl1 (228), and multiple Rab GAPs (231).  Also, in addition to the tyrosine 
kinases discussed previously, the serine-threonine kinase PKCδ and mitogen-activated protein 
kinase p38 are involved in Stx transport from the endosome to the Golgi (232,233).  
SNX1 and SNX2 were not identified in our screen; however, SNX4 was among the top 
candidate hits and enriched for in the cellular component ontology, microtubule associated 
complex.  SNX4p has been associated with SNX41 and SNX42 to transport the v-SNARE, 
SNC1, from the early endosome to the TGN in yeast (234). Mammalian SNX4 plays a similar 
role in trafficking from early endosomes to the endocytic recycling compartment through an 
association with dynein (235).  SNX4 has previously been found to be necessary for trafficking 
of the plant toxin ricin to the Golgi complex (236).   Consistent with the identified function of 
SNX4 and the localization of Stx to Rab11
+
 recycling endosomes, a role for SNX4 in Stx 
trafficking is likely (Figure 4.4, step 1).  The cytoplasmic dynein heavy chain, DYNC1H1, was 
also identified in the screen further suggesting the importance of SNX4.  SNX4 was enriched in 
the microtubule associated complex along with KIF2A, KIF5A, KIF3, KIF22 and ACTR1B. 
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Little is currently known about trafficking of Stx from the recycling endosome to the 
TGN.  A recent study by McKenzie et al. identified EHD1 as being necessary for Stx to reach the 
TGN from the recycling endosome (237).  While there was no enrichment for components in this 
step, a more in depth analysis of the top candidate hits may reveal key regulators (Figure 4.4, 
step 2).  
Stx trafficking from the Golgi to the ER is also not well understood, however studies 
suggest that Rab6 (225) and Cdc42 are important and that transport can be COPI dependent or 
independent (238–240).  One major way in which trafficking to the ER occurs is by recognition 
of a specific amino acid sequence.  Many proteins are targeted to the ER by containing the 
KDEL (Lys-Asp-Glu-Leu) sequence.  KDEL containing proteins that make their way to the 
Golgi are retrieved through interaction with the KDEL receptor and are subsequently returned to 
the ER (241,242).  Unlike toxins such as pseudomonas exotoxin (PE), Stx lacks the ER targeting 
KDEL sequence, yet it is still efficiently targeted to the ER (243).  The signal for Stx to traffic 
from the Golgi to ER has yet to be determined.  Three main hypotheses as to the targeting of Stx 
to the ER were proposed by Johannes and Goud in 1998 (244) and include: (1) an unidentified 
transport sequence within the toxin, (2) targeted transport based on Stx maintaining an 
association with Gb3, or (3) an interaction with a protein that does contain a retrieval sequence.  
The third hypothesis could be addressed with the results of this screen as Stx may associate with 
one or more of the proteins specific to the Golgi or ER identified in this screen for trafficking to 
the ER.  
In addition, TSG101, a component of the ESCRTI complex, and Sec24A, a component of 
COPII coated vesicles important for vesicle targeting, both rescued from Stx suggesting possible 
roles in the Golgi to ER step. BLOC1S4 was identified in the Golgi associated vesicle biogenesis 
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pathway also making it a candidate for further research in this step of Stx trafficking (Figure 4.4, 
step 3). 
Stx is suggested to use the misfolded protein ER-associated degradation (ERAD) 
pathway to translocate from the ER to the cytosol.  The Stx A-subunit has been shown to 
complex with the chaperone HEDJ/Erdj3 and associate with the Sec61 translocon (78).  The ER 
lumen chaperone FKBP2 was identified as a top candidate hit and its relationship to Stx in the 
ER has yet to be demonstrated.  Derlins are a second type of translocon channel in the ER and 
there are limited results investigating their role in Stx translocation to the cytosol.  Our screen 
identified two components that interact within this pathway, HSPA8 and UFD1L (245–247) 
(Figure 4.4, step 4).  These results suggest that more research is needed to understand the 
contribution, if any, of the Derlin complex to Stx translocation to the cytosol, in addition to the 
Sec61 translocon, as it may differ in primary cells.  
Of special interest in the top candidate hits pathways involved in intracellular trafficking 
was neddylation, a post-translational modification similar to ubiquitination, and members of the 
cullin-ring ligases (248).  The binding of NEDD8 to a substrate can cause conformational 
changes, inhibit protein-protein interactions, or promote new interactions.   Cullins are known 
targets of NEDD8 and Cul3 has recently been implicated as having a role in endosomal 
regulation and maturation (249).  Knockdown of Cul3 with siRNA has been shown to inhibit the 
release of influenza A virus from endolysosomes in A549 cells and cause a delay in the 
degradation of epidermal growth factor receptor in HeLa cells (250).  NEDD8 and Cul3 have 
previously been suggested to rescue from Stx based on a small siRNA screen performed by 
Moreau et al. (245).  Moreau et al. confirmed 178 genes as regulating the retrograde trafficking 
of either ricin toxin, pseudomonas exotoxin (PE) or both and tested this set of genes for the 
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ability to rescue from Stx (245).  NEDD8 (identified to rescue from ricin) and Cul3 (identified to 
rescue from PE) were among the top hits to also rescue from Stx.  Additionally, making this 
complex more interesting, is that other components related to the cullin-ring ligases, including 
UBE4A and Cul4B were identified both in Moreau’s screen (245) as rescuing from ricin and PE 
respectively and in our screen.  UBE4A and Cul4B did not fall within the top candidate hits, 
however since they were identified in the overall screen and are related to this pathway, it further 
supports a previously unidentified role for neddylation and cullin-ring ligases in Stx trafficking.  
UBA3, the catalytic subunit of the complex that activates NEDD8, and UCHL1, an ubitquitin 
esterase, were also associated with this enriched pathway.   
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Figure 4.4.  Top candidate hits for intracellular trafficking.  Pathway enrichment for top 
candidate hits involved in the intracellular trafficking of Stx from the early endosome until 
translocation to the cytosol from the ER.  Genes corresponding to enriched pathways are listed.  
After endocytosis, Stx is trafficked from early endosomes (represented by oval marked with 
EEA1) to recycling endosomes (represented by oval marked with Rab11).  From the endosomes 
Stx travels to the TGN (represented by stacked ovals) and then to the ER (represented by the 
stacked crescents on the nucleus represented by the double circles).    
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Genes associated with damage due to catalytic glycosidase activity of Shiga toxin.  
The act of physically cleaving and damaging the rRNA/ribosome initiates signals that 
activate the ribotoxic stress response (RSR) (251).  The RSR leads to the activation of multiple 
kinases, including JNK and p38, and downstream factors that are eventually responsible for the 
upregulation of pro-inflammatory cytokines and apoptosis (252,253).  ZAK has been suggested 
to be the MAPKKK that initiates the RSR induced by Stx (23) and was the top kinase hit in our 
screen.  Other top candidate hits that are involved with rRNA and ribosomes themselves and may 
interact with Stx include NUDT16 and GNB2L1 (Figure 4.5).  
The enzymatic activity of Stx to cleave adenine 4324 in the 28S rRNA, inhibiting tRNA 
binding and protein synthesis, is well established (20).  However, in addition to the N-
glycosidase activity on RNA, Stx is also capable of removing adenines from nuclear DNA in 
vitro and in vivo.  Removal of adenines and damage to the DNA is specific to the enzymatic 
activity of the toxin and not a result of inhibition of ribosomes or apoptosis (254–256).  In vitro 
results show that final breakdown of the DNA caused by Stx is a result of a weakened backbone 
following the creation of multiple apurinic sites (257).  Genes that were enriched in the 
biological process, cellular response to DNA damage stimulus, and may play a role in Stx 
induced DNA damage include c17orf70, FAM175A, PPP4R2, POLL, KIF22, SMC6, FANCL, 
ALKBH3, LIG3 and WRN (Figure 4.5).  Some of the genes identified in this process overlap 
with those associated with apoptosis signaling and therefore may rescue the cell due to an 
inability to signal for and carry out apoptotic pathways. 
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Figure 4.5.  Top candidate hits for damage due to catalytic glycosidase activity.  Pathway 
enrichment for top candidate hits involved in or in response to damage caused by the N-
glycosidase activity of Stx on RNA and DNA.  Genes corresponding to enriched pathways are 
listed.  Upon reaching the cytosol, Stx cleaves rRNA damaging (represented by the lightning 
bolt) the ribosome (represented by the green half circles) and activating the RSR.  Stx has also 
been shown to remove adenines and damage DNA (represented by the blue ribbon and black 
rectangles). 
 
 
 
 
94 
 
Intracellular signaling: Inflammation and apoptosis.  
While tyrosine kinase and PKCδ signaling events directly affect trafficking of Stx, 
activation of apoptotic and inflammatory signaling pathways are the result of the toxic effects of 
Stx on the cell.    These pathways are important as they may play a role in exacerbating disease 
progression.  Stx has been shown to cause upregulation of the synthesis and release of pro-
inflammatory cytokines, through a p38 pathway (258).  Additionally, release of some of these 
factors such as TNFα is suggested to cause upregulation of Gb3 and increase the sensitivity of 
certain cells to toxin (122,129,165).  Enrichment in our screen included components in the 
interferon, tumor necrosis factor (TNF) and toll-like receptor signaling pathways (Figure 4.6).  
Components in the interferon pathway included GBP1, IRF3, STAT1, PTPN2, OAS2 and 
IFNB1.  Genes identified in the TNF pathway included TRAF3 and TNFAIP3, while the toll-like 
receptor pathway included NFKBIE, UBE2V1, IFNB1, IRF3, and TNFAIP3.  Finally, the IL-10 
pathway was also enriched, including genes STAT4, STAT1 and IL-10.  Since this pathway is 
usually associated with being anti-inflammatory, this result was interesting and warrants further 
studies.   IL-10, while normally associated with anti-inflammatory properties, has been shown at 
high levels in immune cells to have pro-inflammatory effects (259).  IL-10 is generally 
associated with immune cells; however, it has been reported to be constitutively produced by 
bronchial epithelial cells in the lung (260).  In the transcriptional profiling shown in Figure 4.1, 
IL-10 had a value of 5.4 which is on the lower side of expression.  Currently, with only 
microarray data we cannot determine what level IL-10 is actually expressed at in RPTECs.  
Further studies are needed to determine if IL-10 is expressed by RPTECs and if high levels can 
have a pro-inflammatory effect similar to that seen in immune cells.    
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Studies suggest that in certain cell types, including THP1, HeLa and HBMEC, retrograde 
transport of Stx holotoxin leads to the activation of the ER stress response and apoptosis 
(164,261,262).  In these cell types, the ER stress response, through activation of multiple factors, 
leads to activation of caspase 3 and apoptosis.  Additionally, Stx has been associated with 
increased BAX expression leading to apoptosis in HEp-2 cells (263).  Multiple factors involved 
in apoptosis signaling were enriched for in our screen, including PIK3C3, BAX, TP53, 
CDKN2A, TRAF3, BIRC6, BMF, TNFRSF10A, IRF3, NFKBIE, NMT1, and STAT1.  
Additionally, many factors involved in p53 apoptosis signaling were also enriched including 
CDKN2A, PIK3C3, WRN, BAX, TNFRSF10A, ZMAT3, TP53, HRAS and NRAS (Figure 4.6).  
A study by Talukder et al. recently suggested that the p53/ATM DNA damage signaling pathway 
was activated by Stx and lead to induction of apoptosis in HeLa cells (264).   
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Figure 4.6.  Top candidate hits for intracellular signaling.  Pathway enrichment for top 
candidate hits involved in intracellular signaling of inflammatory or apoptotic pathways resulting 
from Stx.  Genes corresponding to enriched pathways are listed.  Damage to the cell caused by 
Stx can lead to activation of intracellular signaling pathways including those involved in 
inflammation (represented by red symbol) and apoptosis (represented by fragmented DNA (blue 
ribbons)). 
 
 
 
 
 
 
97 
 
Summary 
 Overall, our siRNA screen of the human genome identified novel components that may 
be important for Stx intoxication of primary RPTECs, which are known to be targeted during the 
course of disease.   Stx intoxication follows a path from binding at the cell surface to retrograde 
transport through to the ER.  Although many components important for the trafficking of Stx 
along this path have been identified, almost all of these studies have been performed in 
immortalized cells that do not play a role during the course of disease.  While it is likely that 
many of these components will also play a role in primary target cells there are expected to be 
additional components that have yet to be identified.  Unfortunately, one of the limitations of a 
siRNA screen is that the siRNAs themselves can have an activating or toxic effect on cells.  
While we were able to confirm some well documented components in the Stx trafficking 
pathway including CLTC and DNM2, we were unable to confirm others such as SYK due to 
possible toxicity of the siRNA to RPTECs.  Overall, while some important genes were likely 
missed due to toxicity of the siRNA, the candidate genes that were identified allowed us to 
identify pathways and particular components of interest that have not been previously identified. 
Validation of novel components will initially require confirming that the candidate gene 
rescues from Stx and that the siRNA used did not have off target effects that increased cellular 
metabolism on its own.  Confirmation of siRNAs could be done with the pools of four siRNAs 
used for the screen, as the pools increase the chance of having at least one siRNA that is 
effective in knocking down expression of the targeted gene.  For candidate hits that were 
confirmed to rescue from Stx toxicity, further experiments could be designed to determine how 
they interact with Stx, directly or indirectly, and then to elucidate the mechanism by which they 
facilitate Stx reaching the cytosol.   
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 The overall implications of this study are significant.  By identifying the trafficking route 
and cellular components utilized by Stx, it opens up a number of new therapeutic targets.  The 
druggable sub-library, which was part of the genome wide screen, contains cellular targets that 
are potential or known targets of currently available therapeutics.  Hits confirmed from this sub-
library could be tested using these therapeutics to determine if they could rescue from toxin both 
in vitro and in vivo.   
Additionally, results of this screen could be used to identify factors that potentiate the 
toxicity of Stx.  We analyzed the screen results for genes that when their expression was reduced 
or absent could rescue from Stx.  Likewise, the results could be analyzed for pathways that when 
expression of genes within them are reduced or absent the toxicity of Stx increases.  An increase 
in toxicity attributed to loss of function of a gene and not an off-target siRNA effect would 
suggest that a particular gene plays a role in attenuating toxicity.  Identifying genes that can 
potentiate Stx toxicity would be important in relation to medications people who become 
infected with STEC may be taking.  This implication is supported by studies such as that by 
Skånland and colleagues who found that β-arrestins are negative regulators of Stx transport 
(265).  Knockdown of β-arrestin increased both Stx transport to the Golgi and Stx toxicity to 
HEp2 cells.  β-arrestin was shown to attenuate p38 signaling which is necessary for Stx 
trafficking from the endosome to Golgi (265).   
 Taken as a whole, the results of this screen offer novel cellular components that may be 
important in the trafficking and therefore toxicity of Stx.  As there are no current treatment 
options and antibiotics are not recommended, new options to manage disease must be explored.  
Inhibiting uptake or trafficking provides multiple targets to prevent Stx from reaching the cytosol 
and exerting toxicity on cells. 
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Conclusions 
 STEC continue to be a persistent issue and pose a significant challenge to the public 
health field.  Additionally, with the acquisition of the phage encoding the stx genes by virulent E. 
coli strains capable of causing higher than usual rates of HUS and neurological complications, it 
could be a growing issue in the years to come.  Although the link between STEC and HUS was 
made 30 years ago, we are still behind in our understanding of the interaction of Stx with 
multiple organs of the body and the mechanisms that dictate uncomplicated resolution versus 
progression to severe disease.  Toxin subtypes further complicate issues since slight variations in 
amino acids have varying effects on disease outcomes.  In the first part of these studies (chapters 
II and III) we aimed to gain a better understanding of the potency of Stx1 and Stx2 subtypes a-d 
on endothelial cells from various vascular beds.  In these studies we found a lack of direct 
toxicity of Stx to most endothelial cells with the exception of dermal microvascular cells.  
Endothelial cells that were resistant to Stx had low or no Gb3 expression and did not bind toxin.  
Many cases of HUS also exhibit neurological dysfunction, though how the toxin gains access to 
the brain and the susceptible cells is not well understood.  We have shown that the endothelial 
cells lining the BBB of both the mouse and human were not susceptible to the direct cytotoxic 
mechanism of Stx2a and are likely not the main target of toxin in the brain in vivo. 
 A large volume of literature exists for the trafficking pathway of Stx, however much of 
the work has been performed using the cervical cancer epithelial cell line, HeLa, or other 
transformed cell lines that lack a direct application to disease.  In the second part of these studies 
(chapter IV) we aimed to define the cellular components necessary for the endocytosis and 
trafficking of Stx2a in primary RPTECs.  Through a genome-wide siRNA screen we identified 
cellular components involved in the trafficking pathway that may be important for Stx in vivo.  
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There are currently no treatment options for HUS, other than supportive care, and treatment with 
several antibiotics is not recommended.  Therefore, the results from this screen could be used to 
identify novel components in the Stx trafficking pathway to be targeted for therapeutic 
intervention.          
 
 
Future Directions 
 
Potency of Stx subtypes on endothelial cells of different origins 
 The results of chapter II suggest that most endothelial cells are not very susceptible to the 
direct toxic action of Stxs.  Unfortunately, the lack of sensitivity of glomerular (GMECs) and 
cerebral cortex (BMECs) endothelial cells did not allow for a detailed examination of any 
differences in the potency of Stx subtypes on cells from organs implicated in playing major roles 
in HUS and associated complications.  Interestingly, microvascular endothelial cells of dermal 
origin were quite sensitive to all Stxs, with ED50 values near 1 ng/ml, except Stx2b to which the 
cells were mostly resistant.  While our studies used dermal microvascular cells (dHMECs) from 
neonates, Ohmi et al. have shown previously that adult dHMECs are also sensitive to the action 
of Stx1 and Stx2a (126), indicating that these cells do not lose significant sensitivity with age.  
Changes in the skin are not often reported in patient autopsies and a direct role for these cells has 
yet to be identified.  However, the level of sensitivity of dHMECs to Stx in vitro warrants further 
studies.  In addition, the sensitivity of mouse dermal endothelial cells should also be assessed to 
determine if they can be used as an in vivo model for studies. 
 While direct toxicity to endothelial cells in the primary organs associated with HUS 
(kidney and brain) was not observed in these studies, dHMECs were highly sensitive to Stx.  As 
discussed briefly in chapter I, Stx at subinhibitory concentrations was found in HUVECs and 
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dHMECs to have little toxic effect; however, it can significantly alter the gene expression of the 
cells (135,136).  The majority of genes regulated by Stx in endothelial cells were cytokines and 
chemokines which is likely more important in the progression of disease to HUS than previously 
appreciated.  The CXCR4/SDF-1 signaling pathway was identified in dHMECs as being 
regulated by Stx.  SDF-1α is known to induce platelet aggregation in the presence of low levels 
of agonist including ADP (266).  Stx2a has been shown to induce the release of SDF-1α from the 
CDC.HMEC-1 dermal cell line (187).  Therefore, studies to further characterize Stx induced 
CXCR4/SDF-1 signaling and its potential involvement in Stx associated HUS are needed.  In 
addition, both gene expression analysis of dHMECs and SDF-1α induced release have only been 
characterized using Stx2a.  Repeating these studies with Stx1 and Stx2 subtypes may provide 
additional insight in to differences that relate to potency. 
 Additionally, the interaction of the B-subunit alone with endothelial cells and the 
initiation of signaling events is an interesting area of future research.  The B-subunits of Stx1 and 
Stx2a have been shown in previous studies to vary in the efficiency and stability of pentamer 
formation which may affect receptor binding (159,267,268).  Since it is necessary for Stx to bind 
the receptor, induce clustering and initiate signaling events at the plasma membrane to be 
endocytosed, the ability to engage the receptor could influence potency potential.  As discussed 
in chapter I, the Stx1 and Stx2a B-subunits have been shown to initiate signaling events at the 
membrane in the absence of the A-subunit, some of which lead to the activation of endothelial 
cells.   The Stx1 and Stx2a B-subunits can induce signaling for the release of unusually large von 
Willebrand factor (ULVWF) from HUVECs and increase platelet adhesion to GMECs (146).  
Stx1B and Stx2aB however were found to initiate signaling leading to the release of ULVWF 
through different pathways (147).  These studies could be repeated with purified Stx2 subtypes 
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b-d B-subunits to determine if all subtypes can induce ULVWF release or if differences exist.  
Finally, the ability of B-subunits from Stx1, Stx2a and the Stx2 subtypes b-d to induce ULVWF 
release could be examined in the highly sensitive dHMECs.     
 
Susceptibility of brain microvascular endothelial cells to Stx2a 
 Stx can increase the permeability of the blood brain barrier (BBB) in mice in vivo 
(115,202), though how this happens is not well understood.  The results of chapter III suggest 
that Stx2a does not exert direct toxicity on brain microvascular endothelial cells from either the 
mouse or human as a means of weakening the BBB.  Since cell death does not appear to be the 
mechanism that leads to increased permeability of the BBB, other routes must be investigated.  
Huber et al. have previously shown that peripheral inflammation caused by administering a pro-
inflammatory compound in the foot pad of rats leads to increased permeability of the BBB (201).  
It was further shown that increased BBB permeability was due to increased paracellular transport 
correlated with changes in endothelial tight junction proteins including occludin and zonula 
occluden-1 (ZO-1).  Stx is known to induce production of inflammatory cytokines (such as TNF-
α and IL-6) (177,204,212) and inflammation; therefore, this could lead to disruption of the BBB 
by affecting the tight junction proteins.  Changes in tight junction proteins of the BBB following 
Stx challenge could be assessed by immunofluorescent staining or by western blots which were 
utilized in the study by Huber (201). 
 The role of the CXCR4/SDF-1 signaling pathway in the brain is also interesting.  
Stimulation of CXCR4 expressing human and mouse astrocytes with SDF-1α induces the release 
of glutamate through a pathway involving TNF-α.  Additionally, SDF-1α induces the release of 
TNF-α from activated, but not resting microglial cells.  The level of TNF-α released is increased 
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when activated microglia are in the presence of astrocytes.  This feedback loop can cause 
increased levels of glutamate release and neurotoxicity (269).  An increase in activated microglia 
have been reported in the brains of humans who have succumb to disease (189) and Stx has been 
shown to stimulate the release of SDF-1α and β from dHMECs (187).  Taken together these 
results suggest a possible pathway that could lead to CNS damage that could be further 
investigated.  The ability of Stx to induce release of SDF-1α/β in BMECs could be determined 
by enzyme linked immunosorbent assay (ELISA).  Depending on the results, further experiments 
could be designed to investigate this pathway. 
 Toxin has been localized in the brain of mice following intraperitoneal challenge (115); 
however, it has yet to be observed in human brains.  While neurons in both the mouse and 
humans have been found to express Gb3 (115,197), how they are affected during the course of 
CNS dysfunction is not well understood.  Overall, a better understanding of the molecular 
mechanisms behind brain dysfunction is needed.  Understanding how the toxin causes 
neurological complications may offer insights in to potential treatments.  
 
siRNA screen to identify novel components of the cell utilized by Shiga toxin 
 To rationally target cellular components with the intent to inhibit the uptake and/or 
trafficking of Stx, it is necessary to understand the pathway used by the toxin in a cell that is 
targeted during the course of human disease.  The results of the genome-wide siRNA screen in 
primary RPTECs (chapter IV) provide multiple areas of future research, some of which have 
been discussed within the chapter.  In addition to characterizing novel interactions of Stx with 
RPTECs, the methods of this screen can be expanded to assaying additional cell types of interest.  
Conditions to run a siRNA screen of the human genome on dHMECs have been optimized and 
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siRNAs have been aliquoted to screening plates.  Screening both epithelial and endothelial cells 
will provide the opportunity to compare trafficking within each cell type.  Additionally, with the 
availability of the siRNA library, screens could be run with Stx1 or Stx2 subtypes to determine if 
there are differences in trafficking that could play a role in the observed epidemiological 
differences in disease severity.  
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